<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">44080</article-id><article-id pub-id-type="doi">10.7554/eLife.44080</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-127112"><name><surname>Nandakumar</surname><given-names>Satish K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7853-426X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-127113"><name><surname>McFarland</surname><given-names>Sean K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-127114"><name><surname>Mateyka</surname><given-names>Laura M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-127115"><name><surname>Lareau</surname><given-names>Caleb A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4179-4807</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-97483"><name><surname>Ulirsch</surname><given-names>Jacob C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127116"><name><surname>Ludwig</surname><given-names>Leif S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127117"><name><surname>Agarwal</surname><given-names>Gaurav</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127118"><name><surname>Engreitz</surname><given-names>Jesse M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5754-1719</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127119"><name><surname>Przychodzen</surname><given-names>Bartlomiej</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127120"><name><surname>McConkey</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-75552"><name><surname>Cowley</surname><given-names>Glenn S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61480"><name><surname>Doench</surname><given-names>John G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3707-9889</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-29245"><name><surname>Maciejewski</surname><given-names>Jaroslaw P</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127121"><name><surname>Ebert</surname><given-names>Benjamin L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-75551"><name><surname>Root</surname><given-names>David E</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-83657"><name><surname>Sankaran</surname><given-names>Vijay G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0044-443X</contrib-id><email>sankaran@broadinstitute.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Division of Hematology/Oncology, Boston Children's Hospital</institution><institution>Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Pediatric Oncology, Dana-Farber Cancer Institute</institution><institution>Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Broad Institute of MIT and Harvard</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Biochemistry Center (BZH)</institution><institution>Ruprecht-Karls-University Heidelberg</institution><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Program in Biological and Medical Sciences</institution><institution>Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution>Harvard Stem Cell Institute</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Harvard Society of Fellows</institution><institution>Harvard University</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">Department of Translational Hematology and Oncology Research, Taussig Cancer Institute</institution><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution content-type="dept">Division of Hematology</institution><institution>Brigham and Women’s Hospital</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution content-type="dept">Department of Medical Oncology</institution><institution>Dana-Farber Cancer Institute</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Howard Hughes Medical Institute</institution><addr-line><named-content content-type="city">Chevy Chase</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Parker</surname><given-names>Stephen</given-names></name><role>Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>McCarthy</surname><given-names>Mark I</given-names></name><role>Senior Editor</role><aff><institution>University of Oxford</institution><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib2"><label>‡</label><p>These authors also contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>09</day><month>05</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e44080</elocation-id><history><date date-type="received" iso-8601-date="2018-12-02"><day>02</day><month>12</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2019-05-08"><day>08</day><month>05</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Nandakumar et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Nandakumar et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-44080-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.44080.001</object-id><p>Genome-wide association studies (GWAS) have identified thousands of variants associated with human diseases and traits. However, the majority of GWAS-implicated variants are in non-coding regions of the genome and require in depth follow-up to identify target genes and decipher biological mechanisms. Here, rather than focusing on causal variants, we have undertaken a pooled loss-of-function screen in primary hematopoietic cells to interrogate 389 candidate genes contained in 75 loci associated with red blood cell traits. Using this approach, we identify 77 genes at 38 GWAS loci, with most loci harboring 1–2 candidate genes. Importantly, the hit set was strongly enriched for genes validated through orthogonal genetic approaches. Genes identified by this approach are enriched in specific and relevant biological pathways, allowing regulators of human erythropoiesis and modifiers of blood diseases to be defined. More generally, this functional screen provides a paradigm for gene-centric follow up of GWAS for a variety of human diseases and traits.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>human genetics</kwd><kwd>genome-wide association studies</kwd><kwd>functional screen</kwd><kwd>hematopoiesis</kwd><kwd>erythropoiesis</kwd><kwd>shRNA</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R33HL120791</award-id><principal-award-recipient><name><surname>Sankaran</surname><given-names>Vijay G</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100003194</institution-id><institution>New York Stem Cell Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sankaran</surname><given-names>Vijay G</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01DK103794</award-id><principal-award-recipient><name><surname>Sankaran</surname><given-names>Vijay G</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A gene-centric functional screen uncovers biological mechanisms underlying genome-wide association study signals for human red blood cell traits.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>As genotyping technologies and accompanying analytical capabilities have continued to improve, genome-wide association studies (GWAS) have identified tens of thousands of variants associated with numerous human diseases and traits. Despite these advances, our ability to discern the underlying biological mechanisms for the vast majority of such robust associations has remained limited, with a few exceptions (<xref ref-type="bibr" rid="bib10">Claussnitzer et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Gupta et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Mohanan et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Musunuru et al., 2010</xref>; <xref ref-type="bibr" rid="bib59">Sankaran et al., 2008</xref>; <xref ref-type="bibr" rid="bib64">Smemo et al., 2014</xref>). In general, published successes have required in-depth mechanistic studies of individual loci and implicated genes to decipher biological mechanisms.</p><p>Recent innovations in functional and computational genomics have advanced the field and enabled more rapid and higher-throughput identification of putative causal variants. Approaches that have shown the most success include the use of massively parallel reporter assays to examine allelic variation (<xref ref-type="bibr" rid="bib66">Tewhey et al., 2016</xref>; <xref ref-type="bibr" rid="bib70">Ulirsch et al., 2016</xref>; <xref ref-type="bibr" rid="bib75">Vockley et al., 2015</xref>) and perturbation approaches for dissecting the necessity of regulatory elements (<xref ref-type="bibr" rid="bib6">Canver et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Fulco et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Simeonov et al., 2017</xref>). In addition, genetic fine mapping approaches have improved our ability to identify putative causal variants among larger sets of variants in linkage disequilibrium (<xref ref-type="bibr" rid="bib27">Guo et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">International Inflammatory Bowel Disease Genetics Consortium et al., 2017</xref>; <xref ref-type="bibr" rid="bib72">Ulirsch et al., 2019</xref>). However, even when putative causal variants are identified at a disease or trait-associated locus, they most often localize to non-coding regions of the genome, making it difficult to connect variants to genes that mediate the observed effects in a scalable manner (<xref ref-type="bibr" rid="bib10">Claussnitzer et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Gupta et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Smemo et al., 2014</xref>).</p><p>In the context of hematopoiesis, GWAS studies have identified thousands of variants associated with various blood cell traits, including hundreds associated with red blood cell traits alone (<xref ref-type="bibr" rid="bib2">Astle et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">van der Harst et al., 2012</xref>). Thorough follow-up efforts at individual loci have identified important regulators of hematopoiesis, such as the key regulator of fetal hemoglobin expression, BCL11A (<xref ref-type="bibr" rid="bib3">Basak et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Sankaran et al., 2008</xref>). However, as in other tissues, the low-throughput with which associated genetic variants can be connected to target genes underlying phenotypes continues to pose a problem for gaining biological insights and clinical actionability in complex traits and diseases.</p><p>To accelerate the rate at which genetic variants can be connected to target genes, high-throughput loss-of-function screens involving putative causal genes underlying the genetic associations can be undertaken. This approach is complementary to conventional variant-focused methods and overcomes bottlenecks that can arise during downstream target gene identification. As a proof-of-principle, we connected variants associated with RBC traits to genes regulating erythropoiesis by directly perturbing all candidate genes in primary human hematopoietic stem and progenitor cells (HSPCs) undergoing synchronous differentiation into the erythroid lineage. We demonstrate unique opportunities to rapidly screen for potential candidate gene mediators and identify networks of biological actors underlying trait-associated variation. We additionally illustrate the value of such screens to uncover previously unappreciated regulators of human hematopoiesis that may serve as key disease modifiers.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Design and execution of an shRNA screen using blood cell trait GWAS hits to identify genetic actors in erythropoiesis</title><p>We applied a gene-centric loss-of-function screening approach to GWAS of RBC traits. We focused on 75 loci associated with RBC traits that were identified by a GWAS performed in up to 135,000 individuals (<xref ref-type="bibr" rid="bib73">van der Harst et al., 2012</xref>) spanning 6 RBC traits (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Importantly, these 75 loci have been robustly replicated in more recently reported association studies performed on larger cohorts and thus represent important targets for perturbation studies (<xref ref-type="bibr" rid="bib2">Astle et al., 2016</xref>; <xref ref-type="bibr" rid="bib72">Ulirsch et al., 2019</xref>). We endeavored to select candidate genes that could potentially underlie these 75 GWAS signals. To do this, each of the 75 sentinel SNPs was first expanded to a linkage disequilibrium (LD) block including all SNPs in high LD (r<sup>2</sup> &gt;0.8, <xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>), then further to the nearest genomic recombination hotspot. Based upon insights from previous expression quantitative trait locus (eQTL) studies (<xref ref-type="bibr" rid="bib45">Montgomery and Dermitzakis, 2011</xref>; <xref ref-type="bibr" rid="bib31">International Inflammatory Bowel Disease Genetics Constortium et al., 2011</xref>; <xref ref-type="bibr" rid="bib74">Veyrieras et al., 2008</xref>), each gene annotated in the genome was expanded to include a wingspan encompassing 110 kb upstream and 40 kb downstream of the transcriptional start and end sites, respectively, to also capture potential functional regulatory elements. This resulted in selection of 389 genes overlapping or in the vicinity of the LD blocks to be tested in the pooled loss-of-function screen. These were distributed at a median of 4 genes per loci (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). This approach may on occasion miss genes targeted by a trait-associated regulatory element. For example, our approach would miss long-range interactions, as is observed at the <italic>FTO</italic> locus with <italic>IRX3/IRX5</italic> (<xref ref-type="bibr" rid="bib10">Claussnitzer et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Smemo et al., 2014</xref>). It is becoming increasingly clear that LD and related metrics will only nominate a fraction of potential regulatory targets (<xref ref-type="bibr" rid="bib78">Whalen and Pollard, 2019</xref>). However, there still exists a nontrivial amount of valid targets within reach of proximity LD approaches, especially when the calculation of such windows are extended to reach the nearest recombination hotspot, suggesting that our approach would capture many candidate target genes.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.44080.002</object-id><label>Figure 1.</label><caption><title>Design and Execution of an shRNA Screen Using Blood Cell Trait GWAS Hits to Identify Genetic Actors in Erythropoiesis.</title><p>(<bold>A</bold>) Overview of shRNA library design.75 loci associated with red blood cell traits (<xref ref-type="bibr" rid="bib73">van der Harst et al., 2012</xref>) were used as the basis to calculate 75 genomic windows of LD 0.8 or greater from the sentinel SNP. Genes with a start site within 110 kb or end site within 40 kb of the LD-defined genomic windows were chosen as candidates to target in the screen. (<bold>B</bold>) Compositional makeup of the library, depicted as number of genes and number of hairpins for each of the four included subcategories; GWAS-nominated genes, erythroid genes, essential genes, and negative control genes (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). (<bold>C</bold>) Primary CD34<sup>+</sup>hematopoietic stem and progenitor cells (HSPCs) isolated from three independent donors were cultured for a period of 16 days in erythroid differentiation conditions. At day 2, cells were infected with the shRNA library, and the abundances of each shRNA were measured at days 4, 6, 9, 12, 14, and 16 using deep sequencing.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.44080.006</object-id><label>Figure 1—source data 1.</label><caption><title>Table containing annotations and information for the 75 SNPs used to seed the shRNA library.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><object-id pub-id-type="doi">10.7554/eLife.44080.007</object-id><label>Figure 1—source data 2.</label><caption><title>Table containing annotations and information for all hairpins, as well as shRNA counts for each time point and replicate.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig1-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Characteristics of GWAS Loci and Gene Selection for Pooled Screen.</title><p>(<bold>A</bold>) Counts of loci from among the original 75 annotated with linkage to each of the six RBC traits, hemoglobin (Hb), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), packed cell volume (PCV), and red blood cell count (RBC).Some loci were associated with multiple traits. Detailed information on each loci available in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. (<bold>B</bold>) Kernel density plot showing the log<sub>10</sub> sizes in bp of the LD-defined genomic windows used to find overlapping genes. (<bold>C</bold>) Histogram showing distribution of number of genes selected using the LD window method at each locus. A median of 4 genes were present at each.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.004</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Feasibility of Loss of Function Approaches to Perform Pooled Screens in Primary Hematopoietic Stem and Progenitor Cells (HSPCs).</title><p>(<bold>A</bold>) Schematic of the loss of function lentiviral constructs tested for pooled screens in primary CD34<sup>+</sup> cells. (<bold>B</bold>) FACS plots showing the proportion of infected GFP<sup>+</sup> cells 4 days after transduction with the respective constructs (MOI -multiplicity of infection). FACS analysis was performed in independent analyzers. (<bold>C</bold>) Efficient silencing of Duffy surface antigen in primary CD34<sup>+</sup> derived erythroid cells by targeting the promoter region using CRISPRi compared to CRISPR constructs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.005</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Pooled shRNA screen in primary HSPCs undergoing erythroid differentiation.</title><p>(<bold>A</bold>) Histogram showing distribution of number of independent hairpins included in the library to target each of the candidate’s genes. (<bold>B</bold>) Representative FACS plots of erythroid cell surface markers CD71 (transferrin receptor) and CD235a (Glycophorin A) expression at various time points during erythroid differentiation at which deep sequencing of shRNAs was performed. Percentages in each quadrant is represented as mean and standard deviation of 3 experiments from independent donors that were uninfected (Mock) or infected with the shRNA library (Pool).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig1-figsupp3-v2.tif"/></fig></fig-group><p>Since the majority of common genetic variation underlying RBC traits appears to act in a cell-intrinsic manner within the erythroid lineage, we decided to perturb the candidate genes during the process of human erythropoiesis (<xref ref-type="bibr" rid="bib20">Giani et al., 2016</xref>; <xref ref-type="bibr" rid="bib61">Sankaran et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Sankaran et al., 2008</xref>; <xref ref-type="bibr" rid="bib70">Ulirsch et al., 2016</xref>). We chose a pooled short hairpin RNA (shRNA) based loss-of-function approach in primary hematopoietic cells to leverage a number of distinct strengths. First, we have had prior success validating individual genes underlying RBC traits using shRNA-based approaches in primary CD34<sup>+</sup> HSPC-derived erythroid cells and our results have been consistent with orthogonal CRISPR based approaches (<xref ref-type="bibr" rid="bib20">Giani et al., 2016</xref>). Second, shRNA libraries can be much more efficiently packaged into lentiviruses and delivered to primary HSPCs compared to alternative CRISPR/Cas9-based guide RNA libraries (<xref ref-type="bibr" rid="bib68">Ting et al., 2018</xref>). We observe that all in one CRISPR or CRISPRi lentiviral constructs that are ideal for primary HSPC screens produce low titer viruses and require very high multiplicities of infection that can be challenging to achieve for a pooled functional screen (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A,B</xref>). Third, the shRNA approach avoids potential complications like non-uniform loss-of-function or gain-of-function outcomes produced by CRISPR/Cas9 based approaches due to unpredictable DNA repair processes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>) (<xref ref-type="bibr" rid="bib40">Mandegar et al., 2016</xref>). Furthermore, shRNAs can act rapidly to achieve gene knockdown and thereby avoid compensatory effects that can occur when complete CRISPR knockout is achieved (<xref ref-type="bibr" rid="bib57">Rossi et al., 2015</xref>), better recapitulating the subtle changes in gene expression that are characteristic of common genetic variation.</p><p>Mobilized peripheral blood-derived primary human CD34<sup>+</sup> HSPCs from three independent healthy donors were infected with a lentiviral-based pooled shRNA library consisting of 2803 hairpins targeting the 389 GWAS-nominated genes, along with 30 control genes (<xref ref-type="bibr" rid="bib43">Moffat et al., 2006</xref>). Each GWAS-nominated gene was targeted with 5–7 distinct shRNAs (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). The set of control shRNAs encompassed essential housekeeping genes as positive controls, negative controls in the form of luciferase and other genes not expressed in humans, and a well-established set of genes known to be important for erythropoiesis (erythroid controls) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Using lentiviral libraries with defined titers, we achieved an infectivity of 35–50%, which provides a good tradeoff between reasonably high infection while minimizing the possibility of multiple integrations per cell that can lead to combinatorial phenotypes. To achieve sufficient library representation, we infected at least 1000 CD34<sup>+</sup> HSPCs per hairpin (7 ~ 11 * 10<sup>6</sup> cells per experiment). The infected HSPCs were cultured using a three-phase semi-synchronous erythroid differentiation method where differentiation blockade reduces cell numbers either through cell death or through a failure of proliferation (<xref ref-type="bibr" rid="bib20">Giani et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Hu et al., 2013</xref>). We hypothesized that hairpins targeting potential regulators of erythropoiesis would be depleted or enriched during the three-phase erythroid culture, similar to our prior experience in analyzing specific GWAS-nominated genes (<xref ref-type="bibr" rid="bib20">Giani et al., 2016</xref>; <xref ref-type="bibr" rid="bib61">Sankaran et al., 2012</xref>; <xref ref-type="bibr" rid="bib70">Ulirsch et al., 2016</xref>). To assay these hairpins, we isolated and deep-sequenced genomic DNA from the pool of infected cells at six different culture time points that represent distinct stages of erythropoiesis to most broadly assess putative causal genes that may act across the span of differentiation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>).</p></sec><sec id="s2-2"><title>Summary characterization of shRNA screen outcomes</title><p>For the vast majority of the ~3000 hairpins included in the library, infection was efficient and consistent. Greater than 95% of hairpins were represented at levels of at least five log<sub>2 </sub>counts per million (CPM) at day 4, two days post-infection (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Across the two-week time course, a diversity of effects - in terms of both increased and decreased hairpin abundance - were observed. While many hairpins were selected against during the course of erythroid differentiation, as reflected in decreases of those hairpin abundances over time, there were also a number of hairpins that increased in the culture over the time course (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.44080.008</object-id><label>Figure 2.</label><caption><title>Summary Characterization of shRNA Screen Outcomes.</title><p>(<bold>A</bold>) Kernel density plot showing library representation as log<sub>2</sub> shRNA CPM across all hairpins. (<bold>B</bold>) shRNA abundance log<sub>2</sub> fold changes from day 4 to day 16. Represented values are the mean of hairpin abundance log<sub>2</sub> fold changes across hairpins for each gene and two standard deviations. (<bold>C</bold>) Kernel density plots representing the day 4 to day 16 log<sub>2</sub> fold changes of hairpin abundances for each of the subcategories of the library, including GWAS-nominated genes, known erythroid essential genes, essential genes to cell viability, and orthogonal genes serving as negative controls. (<bold>D</bold>) Violin plot of day 4 and day 16 log<sub>2</sub> CPM for known actors <italic>GATA1</italic> and <italic>RPS19</italic> and negative controls LacZ and luciferase. (<bold>E</bold>) Log<sub>2</sub> hairpin counts averaged for known actors <italic>GATA1</italic> and <italic>RPS19</italic> as well as negative controls LacZ and luciferase across the course of the experiment. Gray lines depict the universe of all other gene traces in the library for context.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.009</object-id><label>Figure 2—figure supplement 1.</label><caption><title>shRNA abundance log<sub>2</sub> fold changes from day four to each of the other time points.</title><p>Represented values are the mean of hairpin abundance log<sub>2</sub> fold changes across hairpins for each gene and two standard deviations.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.010</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Scatter plots showing agreement of replicate observations across independent CD34<sup>+</sup> donor populations.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig2-figsupp2-v2.tif"/></fig></fig-group><p>The tested set of hairpins targeting genes nominated by the 75 loci showed a variety of activities, forming a broad distribution spanning both decreases and increases in abundance at different time points (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The various controls included in the library behaved as expected. Hairpins targeting genes with known biological roles in erythropoiesis, such as <italic>GATA1</italic> and <italic>RPS19</italic> (<xref ref-type="bibr" rid="bib34">Khajuria et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Ludwig et al., 2014</xref>), showed markedly decreased abundance across the time course. Likewise, hairpins targeting a set of broadly essential genes (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>) were strongly depleted by day 16 when compared to negative control hairpins targeting non-human genes, which showed little if any change (<xref ref-type="fig" rid="fig2">Figure 2C–E</xref>). These trends were recapitulated with strong correlation in each of the three donor CD34<sup>+</sup> cell backgrounds (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p></sec><sec id="s2-3"><title>Statistical modeling of gene effects and accounting for confounders in the shRNA screen</title><p>The resulting observations of hairpin abundance at each time point were used to model the importance of each targeted gene during the process of erythropoiesis. A linear mixed model was implemented to account for the longitudinal nature of the time course data (<xref ref-type="bibr" rid="bib36">Li et al., 2015</xref>) and to handle the confounding off-target and efficiency effects inherent to the shRNA modality (<xref ref-type="bibr" rid="bib56">Riba et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Tsherniak et al., 2017</xref>). Since we wanted our model to be able to detect significant changes in hairpin abundance at any time point throughout the differentiation process, we converted the absolute hairpin abundances at each of the six time points to a log<sub>2</sub> fold change relative to the initial hairpin abundances at the start of the differentiation. Using this metric as our response variable, we pooled together the observations for each of the three donor replicates and specified a fixed effect for each gene to capture the contribution that suppressing it with shRNAs would have on the respective abundances for each of the resulting five time intervals. Given the potential variability that could emerge by using shRNAs, we fit a random effect for each hairpin to minimize the chance of conflating inefficiency or off-target effects with the specific on-target gene effect.</p><p>After fitting this model to the data, we selected our hit set using a two-threshold approach in which both the magnitude and statistical confidence of the estimated gene effect size were considered. Specifically, genes were called as hits if they had a fitted slope &gt;0.1 log<sub>2</sub> fold change per day within the interval while simultaneously possessing a Wald chi-square FDR-adjusted q value &lt; 0.1. This combined approach allowed us to avoid focusing on genes with large, but highly variable or conflicted effects, as well as genes with highly confident but miniscule effects. In total, this approach identified 77 genes at 38 of the 75 targeted loci which, when suppressed, had a significant effect on the slope of shRNA-encoding DNA abundance at any point during the time course. A majority of these hit loci (27 loci) had 1–2 gene targets prioritized (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). These candidate genes were found to be distributed across all 6 of the originally annotated RBC GWAS traits (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), and hairpins targeting them showed strong internal consistency (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.44080.011</object-id><label>Figure 3.</label><caption><title>Statistical Modeling of Gene Effect Accounting for Off-target shRNA Confounders.</title><p>(<bold>A</bold>) Bar graph showing the 38 of 75 loci in the screen with at least one corresponding statistically significant (FDR &lt; 0.1, β &gt;0.1) gene effect causing either a positive or negative log<sub>2</sub> fold change in shRNA abundance.Statistical model output for each gene in screen available in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. (<bold>B</bold>) Kernel density plot showing the expected distributions of K562 essentiality scores using permuted gene hit sets from the library. (<bold>C</bold>) Hairpin rank sums for permuted sets of 5 genes. The red line indicates the enriched rank sums for 5 ‘gold standard’ genes included in the library, <italic>CCND3</italic>, <italic>SH2B3</italic>, <italic>MYB</italic>, <italic>KIT</italic>, and <italic>RBM38</italic>, for each which a genetic basis of action has already been established. (<bold>D</bold>) Permuted distribution of % inclusion of predicted coding variants among the set of identified hits. (<bold>E</bold>) Heat map depicting strength of expression (as z scores within each gene) for each of the 77 identified hit genes across hematopoietic lineages (top) and throughout the specific stages of adult erythropoiesis (bottom). Purple boxes highlight the cell types that were enriched for expression of hit genes. (<bold>F</bold>) Calculated enrichment of the identified hit genes for expression across hematopoietic lineages (top) and throughout the specific stages of adult erythropoiesis (bottom). In both cases, cellular states corresponding to those along the erythropoietic lineage had elevated probability of expressing genes from the hit set as compared to other genes from the library.</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.44080.015</object-id><label>Figure 3—source data 1.</label><caption><title>Table containing the R model output for each gene.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.012</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Additional Characterization of Modeling Outcomes.</title><p>(<bold>A</bold>) Histogram showing the number of gene hits identified at each of the 40 loci with at least one significant gene effect detected. Statistical model output for each gene in screen available in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. (<bold>B</bold>) Bar graph showing the number of gene hits identified for each of the six red blood cell traits used in the original GWAS to identify the studied loci. (<bold>C</bold>) Density-normalized histogram showing the Pearson correlation of hairpin measurements for both genes nominated as hits and genes not nominated as hits.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.013</object-id><label>Figure 3—figure supplement 2.</label><caption><title>K562 Essentiality Scores Comparing Hit Genes vs.Genes Implicated by Other Traits.</title><p>(<bold>A</bold>) Permuted enrichment of essentiality among the set of hit genes vs. randomly chosen sets of genes from the human genome. (<bold>B</bold>) Permuted enrichment of essentiality among the set of hit genes vs. genes implicated by a separate GWAS for LDL cholesterol levels. (<bold>F</bold>) Permuted enrichment of essentiality among the set of hit genes vs. genes implicated by a separate GWAS for HDL cholesterol levels. (<bold>C</bold>) Permuted enrichment of essentiality among the set of hit genes vs. genes implicated by a separate GWAS for blood triglyceride levels.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.014</object-id><label>Figure 3—figure supplement 3.</label><caption><title>Heat map depicting strength of expression (as z scores within each gene) for each of the 77 identified hit genes throughout the specific stages of fetal erythropoiesis.</title><p>Purple boxes highlight the cell types that were enriched for expression of hit genes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig3-figsupp3-v2.tif"/></fig></fig-group><p>To evaluate the validity of this hit set, we began by assaying for enrichment of erythroid essentiality, as recently quantified for each gene in the K562 erythroid cell line (<xref ref-type="bibr" rid="bib76">Wang et al., 2015</xref>). A permutation comparing the sum of K562 essentiality scores for the hit genes with those of randomly drawn, identically-sized gene sets from the library of targeted genes revealed that the hit set was indeed enriched with p=0.0269 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Likewise, when compared to permuted sets of 77 genes randomly chosen from the genome (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>), there was even stronger enrichment for erythroid essentiality with p=0.00021, consistent with the idea that genes in the library likely have stronger essentiality due to their genomic proximity to the GWAS hits. We further explored whether the enrichment could be due to an intrinsic bias inherent to GWAS screening itself by permuting sets of genes from libraries nominated by SNPs associated with low-density lipoprotein levels, high-density lipoprotein levels, and triglyceride levels, finding the hit set to be significantly enriched in all comparisons (<xref ref-type="bibr" rid="bib22">Global Lipids Genetics Consortium et al., 2013</xref>) (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B–D</xref>).</p><p>We further validated the ability of this approach to discover genetically relevant hits by performing a permutation analysis based upon five ‘gold standard’ genes in the library, which possess known genetic underpinnings via identified causal variants: <italic>CCND3</italic> (<xref ref-type="bibr" rid="bib61">Sankaran et al., 2012</xref>; <xref ref-type="bibr" rid="bib72">Ulirsch et al., 2019</xref>), <italic>SH2B3</italic> (<xref ref-type="bibr" rid="bib20">Giani et al., 2016</xref>), <italic>MYB</italic> (<xref ref-type="bibr" rid="bib18">Galarneau et al., 2010</xref>; <xref ref-type="bibr" rid="bib62">Sankaran et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Sankaran et al., 2011</xref>), <italic>KIT</italic> (<xref ref-type="bibr" rid="bib32">Jing et al., 2008</xref>; <xref ref-type="bibr" rid="bib72">Ulirsch et al., 2019</xref>), and <italic>RBM38</italic> (<xref ref-type="bibr" rid="bib70">Ulirsch et al., 2016</xref>). Calculating the rank sums of hairpins ordered by our model’s computed FDR scores for 1,000,000 random combinations of five genes from the library yielded a distribution over which enrichment for the five gold standards was seen with p=0.0249 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). While the vast majority of putative causal variants at the RBC trait-associated loci are in non-coding regions, which can be challenging to use to identify a specific target gene, a subset are in coding regions and thereby nominate a specific gene. As a result, we assayed for the presence of coding variants fine-mapped to the interrogated loci from a recent large GWAS that demonstrated a minimum posterior probability of association of 0.1 among the gene hits and compared this with the overall set of genes interrogated in our library (<xref ref-type="bibr" rid="bib72">Ulirsch et al., 2019</xref>). Collectively, these coding variants were found to be 75% missense, 19% synonymous, and 5% frameshift. Among the 389 GWAS-nominated genes in our library, 20 (~5%) were found to contain at least one coding variant from this list. Of these, there was a significant enrichment observed among the hits (~9%, p=0.03907 as determined by permutation analysis; <xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>Having established genetic confidence in our hit set, we next investigated whether the selected genes satisfied enrichment criterion within the erythroid branch of hematopoiesis. RNA expression values for each of the 77 hit genes were examined in datasets spanning human hematopoiesis (<xref ref-type="bibr" rid="bib11">Corces et al., 2016</xref>), as well as adult and fetal erythropoiesis (<xref ref-type="bibr" rid="bib79">Yan et al., 2018</xref>) (<xref ref-type="fig" rid="fig3">Figure 3E,F</xref>; <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). For each cellular context, gene expression values were z-score normalized for each gene targeted in the screen. Enrichment was tested through permutation by using the sum of expression z-scores at each stage for the called hits as the benchmark, and comparing these to sums derived from expression values from a matching number of genes randomly drawn from the wider screen. In the more holistic hematopoiesis dataset, common myeloid progenitors (CMPs) and megakaryocyte-erythroid progenitors (MEPs) were significantly enriched for hit gene expression (p&lt;0.01). These progenitor populations are known to contain the progenitors that give rise to erythroid cells. Within a more detailed and separate analysis of human adult erythropoiesis, proerythroblast, early basophilic, and late basophilic erythroblast stages were particularly enriched (p&lt;0.001). The stage at which given genes are implicated to play a role in erythropoiesis from the literature likewise often corresponded with the largest magnitude fold changes across the longitudinal time course measurements, as was the case for earlier genes like <italic>RPL7A</italic>, <italic>RPL23A</italic>, <italic>RPS19</italic>, and <italic>KIT</italic> (<xref ref-type="bibr" rid="bib19">Gazda et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Jing et al., 2008</xref>; <xref ref-type="bibr" rid="bib12">DBA Group of Société d'Hématologie et d'Immunologie Pédiatrique-SHIP et al., 2012</xref>) as well as late genes like <italic>SLC4A1</italic> and <italic>ANK1</italic> (<xref ref-type="bibr" rid="bib4">Bennett and Stenbuck, 1979</xref>; <xref ref-type="bibr" rid="bib53">Peters et al., 1996</xref>). To examine how our results compare to target gene identification through eQTL-based approaches, we also examined the whole blood eQTL dataset form the Genotype-Tissue Expression (GTEx) Project, finding that none of the 77 shRNA screen hits emerged using eQTLs located within the LD blocks of the original 75 sentinel SNPs (<xref ref-type="bibr" rid="bib26">GTEx Consortium, 2015</xref>). This is not entirely surprising given that the shRNA screen was performed on differentiating erythroid progenitors which are essentially not present in whole blood, so one would expect to miss cell type-specific effects or eQTLs that act in early progenitor populations. Taken together, these results show that this functional gene-centric screen can identify putative causal genes underlying RBC-trait GWAS hits orthogonal to those that would be found with more conventional eQTL-based methods, and which demonstrate clear enrichment in independent genetic and cell biological datasets. We are therefore able to validate the utility of such an approach to identify biologically-relevant genes underlying human genetic variation and holistically identify potential stages at which such target genes may act to impact the process of hematopoiesis.</p></sec><sec id="s2-4"><title>Analysis of interactions among members of the hit set identifies signaling, structural, and translation-related subnetworks important for erythropoiesis</title><p>By screening all loci and genes at once, our approach afforded us the immediate value of examining associations between hits in a holistic fashion, unearthing both familiar and more novel gene cassettes that play a role in erythropoiesis (<xref ref-type="bibr" rid="bib5">Boyle et al., 2017</xref>). Using STRING interaction network analyses (version 10.5) (<xref ref-type="bibr" rid="bib65">Szklarczyk et al., 2017</xref>), we used empirical, database-curated, co-expression, genomic proximity, and text-mined evidence to identify underlying networks between hits in the screen. These networks highlighted a number of interacting biological processes of both known and previously unappreciated importance to erythropoiesis (<xref ref-type="fig" rid="fig4">Figure 4</xref>), including cell signaling and transcription, cytoskeletal and membrane structure and function, and mRNA translation. We observed a number of molecules that play roles in cell signaling or transcriptional regulation. MYB is a master regulator transcription factor that has been implicated in playing a role in fetal hemoglobin regulation and in erythropoiesis more generally (<xref ref-type="bibr" rid="bib46">Mucenski et al., 1991</xref>; <xref ref-type="bibr" rid="bib77">Wang et al., 2018</xref>). The <italic>MYB</italic> locus has been associated with numerous red blood cell traits (including mean corpuscular volume, mean corpuscular hemoglobin concentration, and RBC count) (<xref ref-type="bibr" rid="bib62">Sankaran et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">van der Harst et al., 2012</xref>). ETO2 (CBFA2T3) is a part of the erythroid transcription factor complex containing TAL1 and is required for expansion of erythroid progenitors (<xref ref-type="bibr" rid="bib23">Goardon et al., 2006</xref>). Both stem cell factor receptor KIT and erythropoietin receptor (EPOR) mediated signaling are essential for erythropoiesis. Our screen identified KIT as one of the factors underlying common genetic variation. CCND3 fills a critical role in regulating the number of cell divisions during terminal erythropoiesis and has been validated as a causal gene associated with variation in RBC counts and size (<xref ref-type="bibr" rid="bib61">Sankaran et al., 2012</xref>; <xref ref-type="bibr" rid="bib72">Ulirsch et al., 2019</xref>).</p><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.44080.016</object-id><label>Figure 4.</label><caption><title>Analysis of Interactions Among Members of the Hit Set Identifies Signaling/Transcription, Membrane, and mRNA Translation-Related Subnetworks Important to Erythropoiesis.</title><p>STRING interaction network analysis identifies signaling/transcription, membrane, and mRNA translation-related subnetworks important to erythropoiesis embedded in the genes identified in the screen hit set. Edges connecting the network are color-coded according to the evidence supporting the interaction. In STRING, this evidence can derive from empirical determination, curation in a database, co-expression of the respective gene nodes, genomic proximity, and text-mining of published literature.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig4-v2.tif"/></fig><p>Interacting networks of hits also emerged in other aspects of red blood cell differentiation and function. One of these centered around membrane and structural cytoskeletal proteins. Our method recovered characteristic RBC genes like solute carrier family 4 member 1 (SLC4A1), also known as band 3, (<xref ref-type="bibr" rid="bib53">Peters et al., 1996</xref>), which serves as a key component of the RBC membrane skeleton. Likewise, it recovered a direct interacting partner for SLC4A1, ankyrin 1 (ANK1), which anchors the cytoskeleton and cell membrane (<xref ref-type="bibr" rid="bib4">Bennett and Stenbuck, 1979</xref>), as well as N-ethylmaleimide Sensitive Factor, vesicle fusing ATPase (NSF), which facilitates membrane vesicle trafficking within the cell (<xref ref-type="bibr" rid="bib21">Glick and Rothman, 1987</xref>).</p><p>Within the realm of mRNA translation, a number of genes emerged as hits that specifically highlight the role of the ribosome. This is interesting in light of recent work that has begun to illuminate erythroid-specific effects of ribosomal perturbations (<xref ref-type="bibr" rid="bib34">Khajuria et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Ludwig et al., 2014</xref>), although a connection between translation and common genetic variation affecting RBC traits has not been previously appreciated. Both <italic>RPL7A</italic> and <italic>RPL19</italic>, for instance, have been implicated by mutations observed in studies of Diamond-Blackfan anemia (<xref ref-type="bibr" rid="bib19">Gazda et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">DBA Group of Société d'Hématologie et d'Immunologie Pédiatrique-SHIP et al., 2012</xref>). The common genetic variation affecting these ribosomal protein genes might contribute to the incomplete penetrance and variable expressivity of anemia seen in Diamond-Blackfan anemia patients (<xref ref-type="bibr" rid="bib71">Ulirsch et al., 2018</xref>). Similar effects have been reported in neurodevelopmental disorders, where common genetic variants may influence phenotypic outcomes in patients (<xref ref-type="bibr" rid="bib50">Niemi et al., 2018</xref>). Non-ribosomal hits in the mRNA metabolism space were also found with both previously established and unknown ties to erythroid-specific phenotypes. Exosome component 9 (EXOSC9), for instance, has been suggested to act as part of the exosome complex as a specific gatekeeper of terminal erythroid maturation (<xref ref-type="bibr" rid="bib41">McIver et al., 2014</xref>). Other unappreciated components, including the tRNA methyltransferase TRMT61A, also were highlighted through this analysis.</p></sec><sec id="s2-5"><title>Transferrin receptor 2 is a negative regulator of human erythropoiesis</title><p>We selected several candidate genes identified by our screen for further validation, given their previously unappreciated roles in human hematopoiesis/erythropoiesis. The first, transferrin receptor 2 (<italic>TFR2</italic>), encodes a protein canonically involved in iron homeostasis that has recently been shown to also regulate EPO receptor signaling (<xref ref-type="bibr" rid="bib16">Forejtnikovà et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Nai et al., 2015</xref>). Although TFR2 has been studied in the context of murine erythropoiesis, its role in human erythropoiesis has not been assessed. To validate TFR2 as a regulator of human erythropoiesis, we performed individual knockdown experiments using lentiviral shRNAs in primary human CD34<sup>+</sup> HSPCs undergoing erythroid differentiation. Significant knockdown of TFR2 was observed at both the mRNA (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) and protein levels (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) using two independent shRNAs from among the six targeting TFR2 in the screen. Though two of the six were outliers, the two chosen here for follow-up were part of the consensus group of four showing similar effects. Downregulation of TFR2 increased erythroid differentiation as observed by increased expression of erythroid-specific cell surface markers CD235a and CD71 at day 9 (shLUC ~22%; TFR2 sh1 ~42%; TFR2 sh2 ~40%) and day 12 of culture (shLUC ~60%; TF2 sh1 ~80%; TFR2 sh2 ~80%) (<xref ref-type="fig" rid="fig5">Figure 5C and E</xref>). Downregulation of TFR2 also improved the later stages of erythroid differentiation/maturation, as observed by loss of cell surface marker CD49d at day 15 of culture, an increased rate of enucleation, and through assessment of cell morphology (<xref ref-type="fig" rid="fig5">Figure 5D</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>). Previous studies have reported the isolation of TFR2 as a component of the erythropoietin (EPO) receptor complex (<xref ref-type="bibr" rid="bib16">Forejtnikovà et al., 2010</xref>). To test if downregulation of TFR2 can result in increased EPO signaling <xref ref-type="bibr" rid="bib35">Kim et al. (2017)</xref>, we measured EPO-dependent STAT5 phosphorylation after TFR2 knockdown in UT7/EPO cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). TFR2 downregulation resulted in significantly higher pSTAT5 phosphorylation in comparison to the control with EPO stimulation from 0.02 U/mL to 200 U/mL (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). In addition, the maximal pSTAT5 response could be achieved within a shorter period of EPO stimulation upon TFR2 downregulation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Given our findings that TFR2 is a negative regulator of EPO signaling, it may be an ideal therapeutic target for conditions characterized by ineffective erythropoiesis like β-thalassemia (<xref ref-type="bibr" rid="bib58">Rund and Rachmilewitz, 2005</xref>). A recent study has supported this hypothesis, showing that Tfr2 downregulation is beneficial in a mouse model of β-thalassemia (<xref ref-type="bibr" rid="bib1">Artuso et al., 2018</xref>).</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.44080.017</object-id><label>Figure 5.</label><caption><title>Transferrin receptor two is a Negative Regulator of Human Erythropoiesis.</title><p>(<bold>A</bold>) Quantitative RT-PCR and (<bold>B</bold>) Western blot showing the expression of TFR2 in human CD34<sup>+</sup> cells five days post-infection with the respective lentiviral shRNAs targeting TFR2 (TFR2 sh1 and sh2) and a control luciferase gene (shLUC). (<bold>C</bold>) Representative FACS plots of erythroid cell surface markers CD71 (transferrin receptor) and CD235a (Glycophorin A) expression at various time points during erythroid differentiation. Percentages in each quadrant are represented as mean and standard deviation of 3 independent experiments (<bold>D</bold>) Hoechst staining showing more enucleated cells after TFR2 knockdown at day 21 of erythroid culture. (<bold>E</bold>) Representative histogram plots showing increased expression of CD235a (Glycophorin A) after TFR2 knockdown (<bold>F</bold>) Enhanced pSTAT5 response after TFR2 knockdown in UT7/EPO cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.018</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Additional Analysis Showing Transferrin Receptor two is a Negative Regulator of Human Erythropoiesis.</title><p>(<bold>A</bold>) Representative FACS plots of alternate erythroid cell surface markers CD49d (α4 integrin) and CD235a (Glycophorin A) expression at various time points during erythroid differentiation. (<bold>B</bold>) May-Grunwald Giemsa staining showing more differentiated erythroid cells after TFR2 knockdown at day 18 of erythroid culture. (<bold>C</bold>) Western blot showing downregulation of TFR2 in UT7/EPO cells. (<bold>D</bold>) Time-dependent absolute value of Mean Fluorescence Intensity (MFI) of STAT5 in UT7/Epo cells after TFR2 knockdown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>SF3A2 is a key regulator of human erythropoiesis and is a disease modifier in a murine model of myelodysplastic syndrome</title><p>Extensive mRNA splicing occurs during the terminal stages of erythropoiesis (<xref ref-type="bibr" rid="bib55">Pimentel et al., 2016</xref>). However, key regulators of this process remain largely undefined. Our study uncovered splicing factor 3A subunit 2 (SF3A2) in the subnetwork of erythropoiesis signaling and transcription hits (<xref ref-type="fig" rid="fig4">Figure 4</xref>). SF3A2 specifically was associated with maximal hairpin drop out at day 12 (FDR = 0.005) – a later time point in erythropoiesis. SF3A2 is a component of the U2SNRP complex whose binding to the branch point is critical for proper mRNA splicing (<xref ref-type="bibr" rid="bib24">Gozani et al., 1996</xref>; <xref ref-type="bibr" rid="bib25">Gozani et al., 1998</xref>). Knockdown of SF3A2 in primary human CD34<sup>+</sup> HSPCs results in decreased cell numbers during erythroid differentiation starting from day 7 (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). To measure early effects of SF3A2 and to exclude potential toxicity of puromycin selection, we replaced the puromycin resistance gene with a GFP encoding cDNA in the lentiviral shRNA constructs. We achieved similar infection (30–40% on day 6) at the early time points between controls (shLuc) and shRNAs targeting <italic>SF3A2</italic> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). During erythroid differentiation, we observed a reduction in GFP-expressing cells comparable to the decreased cell numbers seen with the puromycin resistant constructs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Decreased cell numbers were associated with decreased erythroid differentiation as measured by erythroid surface markers CD71 and CD235a (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). We also observed an increase in non-erythroid lineages based on surface marker expression of CD11b (myeloid) and CD41a (megakaryocytic) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>).</p><fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.44080.019</object-id><label>Figure 6.</label><caption><title>SF3A2 is a Key regulator of Human Erythropoiesis and Modulates Erythropoiesis Defects in a Murine Model of MDS.</title><p>(<bold>A</bold>) Quantitative RT-PCR and (<bold>B</bold>) Western blot showing the expression of SF3A2 in human CD34<sup>+</sup> cells five days post-infection with the respective lentiviral shRNAs targeting <italic>SF3A2</italic> (sh1-4) and a control luciferase gene (shLUC). (<bold>C</bold>) Growth curves showing that downregulation of SF3A2 results in reduced total cell numbers during erythroid differentiation from three independent experiments. (<bold>D</bold>) Representative FACS plots of erythroid cell surface markers CD71 (transferrin receptor) and CD235a (Glycophorin A) expression at various time points during erythroid differentiation. Percentages in each quadrant are represented as mean and standard deviation of three independent experiments (<bold>E</bold>) Altered splicing events identified by RNA-Seq analysis of stage matched erythroid cells (shSF3A2 vs. shLUC). Overlapping changes observed in <italic>SF3B1</italic> mutant BM cells from MDS patients (Obeng et al) (<xref ref-type="supplementary-material" rid="fig6sdata5">Figure 6—source data 5</xref> and <xref ref-type="supplementary-material" rid="fig6sdata6">6</xref>). Differentially expressed genes and pathway analysis available in <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>–<xref ref-type="supplementary-material" rid="fig6sdata4">4</xref>. (<bold>F</bold>) Lineage negative bone marrow cells from wildtype (WT) and <italic>Sf3b1<sup>K700E</sup></italic> mice were infected with shRNAs targeting murine <italic>Sf3a2</italic> gene co-expressing a reporter GFP gene. Percentage of Ter119<sup>+</sup> CD71<sup>+</sup> erythroid cells within the GFP compartment after 48 hr in erythroid differentiation. (<bold>G</bold>) Total cell numbers of GFP<sup>+</sup> erythroid cells after 48 hr in erythroid differentiation.</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.44080.022</object-id><label>Figure 6—source data 1.</label><caption><title>Table containing the DESeq2 output for differentially expressed genes in cells undergoing SF3A2 knockdown or control shRNA treatment.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig6-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><object-id pub-id-type="doi">10.7554/eLife.44080.023</object-id><label>Figure 6—source data 2.</label><caption><title>Table containing the DESeq2 output for differentially expressed genes in MDS patients with and without mutations in <italic>SF3B1</italic>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig6-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><object-id pub-id-type="doi">10.7554/eLife.44080.024</object-id><label>Figure 6—source data 3.</label><caption><title>Tables containing the GO component (Table 1) and function (Table 2) enrichments calculated using GOrilla for cells undergoing SF3A2 knockdown or control shRNA treatment.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig6-data3-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><object-id pub-id-type="doi">10.7554/eLife.44080.025</object-id><label>Figure 6—source data 4.</label><caption><title>Tables containing the GO component (Table 1) and function (Table 2) enrichments calculated using GOrilla for MDS patient samples with and without mutations in <italic>SF3B1</italic>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig6-data4-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata5"><object-id pub-id-type="doi">10.7554/eLife.44080.026</object-id><label>Figure 6—source data 5.</label><caption><title>Tables containing the differential splicing analysis for cells undergoing SF3A2 knockdown or control shRNA treatment.</title><p>Categories of splice mutations presented in each table are alternative 3’ splice sites, alternative 5’ splice sites, mutually exclusive exons, retrained introns, and skipped exons, respectively.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig6-data5-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata6"><object-id pub-id-type="doi">10.7554/eLife.44080.027</object-id><label>Figure 6—source data 6.</label><caption><title>Tables containing the differential splicing analysis for MDS patient patient samples with and without mutations in <italic>SF3B1</italic>.</title><p>Categories of splice mutations presented in each table are alternative 3’ splice sites, alternative 5’ splice sites, mutually exclusive exons, retrained introns, and skipped exons, respectively.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44080-fig6-data6-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.020</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Additional Analysis Showing SF3A2 is Required for Human Erythropoiesis.</title><p>(<bold>A</bold>) shRNAs targeting <italic>SF3A2</italic> co-expressing a reporter GFP gene was infected into human CD34<sup>+</sup> cells and cultured in erythroid conditions. GFP expression at various time points from three independent experiments show that downregulation of SF3A2 results in reduced cell numbers. (<bold>B</bold>) Representative FACS plots of erythroid (CD235a) and non-erythroid cell surface markers (CD11b/CD41 a) and at various time points showing an increase in non-erythroid lineages upon SF3A2 downregulation. Cells were gated on the GFP positive population.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.44080.021</object-id><label>Figure 6—figure supplement 2.</label><caption><title>Additional Analysis of Erythropoiesis Defects Observed in <italic>Sf3b1</italic><sup>K700E</sup> Murine Erythroid Cells upon SF3A2 knockdown.</title><p>(<bold>A</bold>) Knockdown efficiency of shRNAs targeting <italic>SF3A2</italic> in murine erythroleukemia (MEL) cells by western blot. (<bold>B</bold>) Total cell numbers of GFP +shRNA expressing bone marrow cells from wildtype (WT) and <italic>Sf3b1</italic><sup>K700E</sup> mice at the start of murine erythroid differentiation. (<bold>C</bold>) Percentage of Ter119<sup>+</sup> CD71<sup>+</sup> erythroid cells within GFP compartment and (<bold>D</bold>) Total cell numbers of GFP<sup>+</sup> erythroid cells after 24 hr in erythroid differentiation. (<bold>E</bold>) Growth curves of GFP<sup>+</sup> erythroid cells during erythroid culture. (<bold>F</bold>) Putative but insignificant interaction between <italic>SF3A2</italic> variant alleles (rs25672) and hemoglobin levels in MDS patients with <italic>SF3B1</italic> mutations.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-44080-fig6-figsupp2-v2.tif"/></fig></fig-group><p>To identify the molecular mechanisms underlying the reduced differentiation of erythroid cells, we sorted stage-matched CD71<sup>+</sup>/CD235a<sup>+</sup> cells and performed RNA-Seq analysis. We also ran this analysis in parallel for data from hematopoietic progenitors of patients with myelodysplastic syndrome (MDS), a disorder well-known for significant impairments in terminal erythropoiesis, either with or without somatic mutations in the related splicing factor <italic>SF3B1</italic> (<xref ref-type="bibr" rid="bib51">Obeng et al., 2016</xref>). Cells treated with shRNA to suppress SF3A2 were found to differentially express 6061 genes with an adjusted p value &lt; 0.05 as compared to the shLuc control, whereas only 807 genes were differentially expressed given the same threshold cutoff in the MDS patients with an <italic>SF3B1</italic> mutations compared to those without (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Genes from both the SF3A2 differentially expressed set and the SF3B1 differentially expressed set were significantly enriched for structural constituents of the ribosome (p&lt;3.2×10<sup>−44</sup> and p&lt;7.5×10<sup>-24,</sup> respectively) among other cellular components and functions (<xref ref-type="supplementary-material" rid="fig6sdata3">Figure 6—source data 3</xref> and <xref ref-type="supplementary-material" rid="fig6sdata4">4</xref>). Examining differential splicing in the set of genes not differentially expressed in either condition, both were found to exhibit a similar proportion of altered splicing events, including alternative 3’ splice sites, alternative 5’ splice sites, mutually exclusive exons, and skipped exons (<xref ref-type="fig" rid="fig6">Figure 6E</xref>).</p><p>We therefore wanted to further explore this connection between SF3A2 and its role in common variation in RBC traits with SF3B1 and the role it plays in the pathogenesis of MDS. To this end, we utilized a recently developed faithful mouse model harboring the <italic>Sf3b1</italic><sup>K700E</sup> mutation that displays characteristic features of MDS, including an anemia due to impaired erythropoiesis (<xref ref-type="bibr" rid="bib51">Obeng et al., 2016</xref>). We tested if downregulation of Sf3a2 could worsen the already impaired erythropoiesis seen in these animals. Equal numbers of lineage-negative HSPCs were isolated from bone marrow of wild-type and <italic>Sf3b1</italic><sup>K700E</sup> mice and infected with shRNAs targeting Sf3a2 and then erythroid differentiation was induced (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A,B</xref>). Consistent with previous reports, we observed that <italic>Sf3b1</italic><sup>K700E</sup> cells show reduced erythroid differentiation and cell growth compared to wild-type cells infected with control non-targeting shRNAs (<xref ref-type="fig" rid="fig6">Figure 6F,G</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2C–E</xref>). Downregulation of Sf3a2 using two independent shRNAs further worsens the defects in both erythroid differentiation and cell growth observed for <italic>Sf3b1</italic><sup>K700E</sup> cells (<xref ref-type="fig" rid="fig6">Figure 6F,G</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2C–E</xref>). This data suggest that modulation of SF3A2 could modify the alterations of erythropoiesis observed in the setting of somatic <italic>SF3B1</italic> MDS-causal mutations. This form of MDS is characterized by significant variation in the degree of anemia found at the time of presentation (<xref ref-type="bibr" rid="bib9">Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium et al., 2011</xref>). We therefore attempted to examine whether such common genetic variation could contribute to such phenotypic variation. We identified a coding SNP, rs25672, in LD with the sentinel SNP at the locus, rs2159213 (r<sup>2</sup> = 0.737675 in CEU 1000 Genomes phase 3), in which <italic>SF3A2</italic> was the only gene identified by the linear mixed model as a hit. Prevalence of the alternate ‘G’ allele (which corresponds to the prevalence of the ‘C’ effect for <italic>SF3A2</italic>) is correlated with an increase in hemoglobin levels () that was likely insignificant due to the limited number of patients studied here. Unfortunately, larger cohorts in such a relatively rare disorder could not be identified. However, these findings suggest that the subtle variation noted in populations at the rs2159213 locus containing <italic>SF3A2</italic> may more profoundly cause variation among individuals with an acquired blood disorder, such as MDS, illustrating the value of such a gene-centric study to identify potential disease modifiers.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>A major challenge in moving from GWAS-nominated variants to function is to identify potential target genes systematically. While many functional follow up approaches focus on causal variants, we reasoned that a gene-centered approach may be complementary to other emerging methods and represent a scalable approach for gaining broad insights into GWAS. To this end, we designed and executed a GWAS-informed high-throughput loss-of-function screen to identify key players in primary human HSPCs undergoing erythroid differentiation. Such dynamic in vitro systems afford a unique window through which to longitudinally screen, enabling unique insights to be gained into inherently non-stationary biological processes like erythropoiesis. The screen identified 77 gene hits at 38 of the original 75 loci used to design the library. Collectively, these hits had strongly amplified essentiality in erythroid cell lines, included a significant proportion of known, genetically-linked ‘gold standard’ erythroid genes, and were enriched for red blood cell trait-associated coding variants orthogonally identified through genetic fine-mapping. From a holistic perspective, the network of interacting gene hits highlighted a number of high-level biological components and pathways important for erythropoiesis, including specific signaling and transcription factors, membrane and structural components, and components involved in mRNA translation. It is interesting to note that the hits identified by our screen did not overlap those that would be identified with eQTLs from whole blood, which emphasizes how studies of variation in developing hematopoietic cells may not be accurately reflected by studies of circulating blood cells. It does, however, lend credence to the notion that there are complementary insights to be gained through these differing methods.</p><p>Functional follow-up on <italic>SF3A2</italic> and <italic>TFR2</italic>, two gene hits identified in the screen, were fruitful in elucidating mechanistic ties between alteration in mRNA splicing and EPO signaling activity, respectively, to observed perturbation of erythroid phenotypes. In addition, our studies suggest that at least SF3A2, and potentially other regulators such as some implicated mRNA translation factors, may be key disease modifiers that alter the impaired erythropoiesis seen in diseases like MDS or Diamond-Blackfan anemia. These outcomes strongly recommend further exploration of this approach as a rapid means to screen for genes underlying human erythroid differentiation, with the potential to connect back and explain the phenotypic links in GWAS studies. Moreover, since shRNA-based loss-of-function screens are readily accessible and offer demonstrated compatibility with primary cell model systems, we believe this approach provides a method that is portable and can be applied across a variety of lines of biological inquiry.</p><p>However, it is not a universal solution, and there are certainly a number of considerations that must be kept in mind regarding the extent to which this type of assay can be adopted across other diseases and traits. We acknowledge for it to be useful to a given research question, a suitable system capable of modeling the trait/disease of interest must first exist, and for many cellular systems this is often challenging. Fortunately, this is a shortcoming that will diminish over time as our understanding of human biology and our ability to faithfully recapitulate in vivo microenvironments and processes improves, though this may be a distant prospect for exquisitely complex tissues like the brain or for traits/diseases that involve a larger number of cell types/interactions. Likewise, the use of shRNAs as the vehicle for perturbation carries with it unique challenges, chief among them the proclivity of shRNA to exert confounding off-target effects when compared to CRISPR-based methods. While this is true and unavoidable, the inclusion of appropriate controls, both at the experimental level and in modeling off-target contributors to observed phenotypic effects, provide an effective means to address this issue (<xref ref-type="bibr" rid="bib69">Tsherniak et al., 2017</xref>). We chose to perform our screen in primary hematopoietic cells and thus were partially limited experimentally to the use of shRNA-based suppressive approaches. Finally, evidence has recently been published that the targets of identified non-coding variants are occasionally not within linkage disequilibrium blocks in the genome (<xref ref-type="bibr" rid="bib78">Whalen and Pollard, 2019</xref>). This does not necessarily conflict with our results, since we identify hits at only 38 of 75 examined loci and provides an intriguing direction for further work that may elucidate how genetic and epigenomic structural blocks in the human genome can provide complementary information.</p><p>Our data show that gene-centric screens are valuable for GWAS follow-up. They are not limited to red cell traits and may be useful for other human traits/diseases, as has begun to be shown in diseases like type 2 diabetes (<xref ref-type="bibr" rid="bib67">Thomsen et al., 2016</xref>). Data from such screens can be integrated with complementary insights gleaned from variant centric screens. Ultimately this could accelerate our understanding of human hematopoiesis and other biological processes, and aid in the development of applicable therapies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Biological sample (Homo sapiens)</td><td valign="top">CD34 + mobilized peripheral blood</td><td valign="top">Fred Hutchinson Cancer Research Center</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Cell line (Homo sapiens)</td><td valign="top">UT-7/EPO</td><td valign="top">NA</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_5202">CVCL_5202</ext-link></td><td valign="top">maintained in Sankaran laboratory</td></tr><tr><td valign="top">Cell line (Mus musculus)</td><td valign="top">MEL</td><td valign="top">NA</td><td valign="top"/><td valign="top">maintained in Sankaran laboratory</td></tr><tr><td valign="top">Genetic reagent (Mus musculus)</td><td valign="top"><italic>Sf3b1</italic><sup>K700E</sup></td><td valign="top"><xref ref-type="bibr" rid="bib51">Obeng et al., 2016</xref></td><td valign="top"/><td valign="top">Dr. Benjamin L. Ebert (Brigham Women's Hospital, Boston MA)</td></tr><tr><td valign="top">Recombinant DNA reagent (lentiviral shRNA)</td><td valign="top">PLKO.1-Puro (plasmid)</td><td valign="top">Sigma-Aldrich</td><td valign="top">RRID <break/>:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_10878">Addgene_10878</ext-link></td><td valign="top">Pol III based shRNA backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (lentiviral shRNA)</td><td valign="top">PLKO-GFP (plasmid)</td><td valign="top">this paper</td><td valign="top"/><td valign="top">GFP version of pLKO.1-Puro</td></tr><tr><td valign="top">Recombinant DNA reagent (lentiviral shRNA)</td><td valign="top">SFFV-Venus-mir30 shRNA (plasmid)</td><td valign="top">this paper</td><td valign="top"/><td valign="top">Pol II based shRNA backbone</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-human CD235a-APC</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#: 17-9987-42; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2043823">AB_2043823</ext-link></td><td valign="top">FACS (5 ul per test)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-human CD71-FITC</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#: 11-0719-42; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1724093">AB_1724093</ext-link></td><td valign="top">FACS (5 ul per test)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-human CD71-PEcy7</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#: 25-0719-42; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2573366">AB_2573366</ext-link></td><td valign="top">FACS (5 ul per test)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal ant-human CD49d-PE</td><td valign="top">Miltenyi Biotec</td><td valign="top">Cat#: 130-093-282; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1036224">AB_1036224</ext-link></td><td valign="top">FACS (10 ul per test)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-human CD41a-PE</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#: 12-0419-42; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10870785">AB_10870785</ext-link></td><td valign="top">FACS (5 ul per test)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-human CD11b-PE</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#: 12-0118-42; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2043799">AB_2043799</ext-link></td><td valign="top">FACS (5 ul per test)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rat monoclonal anti-mouse Ter119-APC</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#: 17-5921-82; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_469473">AB_469473</ext-link></td><td valign="top">FACS (0.25 ug/test)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rat monoclonal anti-mouse CD71-PE</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#: 12-0711-82; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_465740">AB_465740</ext-link></td><td valign="top">FACS (0.5 ug/test)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-phospho STAT5 Alexa Fluor-647</td><td valign="top">BD Bioscience</td><td valign="top">Cat#: 612599; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_399882">AB_399882</ext-link></td><td valign="top">FACS (1:20)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-GAPDH</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">sc-32233; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_627679">AB_627679</ext-link></td><td valign="top">Western (1:20,000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-TFR2</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">sc-32271; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_628395">AB_628395</ext-link></td><td valign="top">Western (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-SF3A2</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">sc-390444</td><td valign="top">Western (1:1000)</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">shLUC</td><td valign="top">Sigma-Aldrich</td><td valign="top">TRCN0000072259</td><td valign="top">5’- CGCTGAGTACTTCGAAATGTC-3’</td></tr><tr><td valign="top">Sequence-based <break/>reagent</td><td valign="top">TFR2 sh1 (human)</td><td valign="top">Sigma-Aldrich</td><td valign="top">TRCN0000063628</td><td valign="top">5’-GCCAGATCACTACGTTGTCAT-3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">TFR2 sh2 (human)</td><td valign="top">Sigma-Aldrich</td><td valign="top">TRCN0000063632</td><td valign="top">5-CAACAACATCTTCGGCTGCAT-3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SF3A2 sh1 (human)</td><td valign="top">Sigma-Aldrich</td><td valign="top">TRCN0000000060</td><td valign="top">5’-CTACGAGACCATTGCCTTCAA-3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SF3A2 sh2 (human)</td><td valign="top">Sigma-Aldrich</td><td valign="top">TRCN0000000061</td><td valign="top">5’-CCTGGGCTCCTATGAATGCAA-3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SF3A2 sh3 (human)</td><td valign="top">Sigma-Aldrich</td><td valign="top">TRCN0000000062</td><td valign="top">5’-CAAAGTGACCAAGCAGAGAGA-3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SF3A2 sh4 (human)</td><td valign="top">Sigma-Aldrich</td><td valign="top">TRCN0000000063</td><td valign="top">5’-ACATCAACAAGGACCCGTACT-3’</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">RNeasy Mini Kit</td><td valign="top">QIAGEN</td><td valign="top">Cat#: 74104</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">iScript cDNA synthesis Kit</td><td valign="top">Bio-Rad</td><td valign="top">Cat#: 1708891</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">iQ SYBR Green Supermix</td><td valign="top">Bio-Rad</td><td valign="top">Cat#: 170–8882</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NucleoSpin Blood XL-Maxi kit</td><td valign="top">Clonetch</td><td valign="top">Cat#: 740950.1</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Lineage Cell Depletion Kit (mouse)</td><td valign="top">Miltenyi</td><td valign="top">Cat#: 130-090-858</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Nextera XT DNA Library Preparation Kit</td><td valign="top">Illumina</td><td valign="top">Cat#: FC-131–1096</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NextSeq 500/550 High Output Kit v2.5 (75 Cycles)</td><td valign="top">Illumina</td><td valign="top">Cat#: 20024906</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Bioanalyzer High Sensitivity DNA Analysis</td><td valign="top">Agilent</td><td valign="top">Cat#: 5067–4626</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Agencourt AMPure XP</td><td valign="top">Beckman-Coulter</td><td valign="top">Cat#: A63881</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">TaKaRa Ex TaqDNA Polymerase</td><td valign="top">Takara</td><td valign="top">Cat#: RR001B</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Qubit dsDNA HS Assay Kit</td><td valign="top">Thermo Fisher</td><td valign="top">Cat#: Q32854</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Human Holo-Transferrin</td><td valign="top">Sigma Aldrich</td><td valign="top">Cat#: T0665-1G</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Humulin R (insulin)</td><td valign="top">Lilly</td><td valign="top">NDC 0002-8215-01</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Heparin</td><td valign="top">Hospira</td><td valign="top">NDC 00409-2720-01</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Epogen (recombinant erythropoietin)</td><td valign="top">Amgen</td><td valign="top">NDC 55513-267-10</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Recombinant human stem cell factor (SCF)</td><td valign="top">Peprotech</td><td valign="top">Cat#: 300–07</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Recombinant human interleukin-3 (IL-3)</td><td valign="top">Peprotech</td><td valign="top">Cat#: 200–03</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Recombinant mousestem cell factor (SCF)</td><td valign="top">R&amp;D systems</td><td valign="top">Cat# 455-MC-010</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">recombinant mouse Insulin like Growth Factor 1 (IGF1)</td><td valign="top">R&amp;D systems</td><td valign="top">Cat# 791 MG-050</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Hoechst 33342</td><td valign="top">Life Technologies</td><td valign="top">Cat#: H1399</td><td valign="top">FACS (1:1000)</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Fixation Buffer</td><td valign="top">BD Bioscience</td><td valign="top">Cat#: 554655</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Perm Buffer III</td><td valign="top">BD Bioscience</td><td valign="top">Cat#: 558050</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">May-Grünwald Stain</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat#: MG500</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Giemsa Stain</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat#: GS500</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">STAR</td><td valign="top"><xref ref-type="bibr" rid="bib13">Dobin et al., 2013</xref></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015899">SCR_015899</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MISO</td><td valign="top"><xref ref-type="bibr" rid="bib33">Katz et al., 2010</xref></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003124">SCR_003124</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">R</td><td valign="top">The R Foundation</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_001905">SCR_001905</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Salmon</td><td valign="top"><xref ref-type="bibr" rid="bib52">Patro et al., 2017</xref></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_017036">SCR_017036</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GOrilla</td><td valign="top"><xref ref-type="bibr" rid="bib15">Eden et al., 2009</xref></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_006848">SCR_006848</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">VEP</td><td valign="top"><xref ref-type="bibr" rid="bib42">McLaren et al., 2016</xref></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_007931">SCR_007931</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FlowJo version 10</td><td valign="top">FlowJo</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008520">SCR_008520</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad Prism 7</td><td valign="top">GraphPad Software Inc</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Python 2, 3</td><td valign="top">Python Software Foundation</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008394">SCR_008394</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">PLINK</td><td valign="top"><xref ref-type="bibr" rid="bib7">Chang et al., 2015</xref></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_001757">SCR_001757</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">PoolQ</td><td valign="top">Broad Institute</td><td colspan="2" valign="top"><ext-link ext-link-type="uri" xlink:href="https://portals.broadinstitute.org/gpp/public/software/poolq">https://portals.broadinstitute.org/gpp/public/software/poolq</ext-link></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Design of the shRNA library</title><p>PLINK version 1.9 and 1000 genomes phase one data were utilized to expand 75 SNPs previously identified in a RBC trait GWAS to include a genomic region in linkage disequilibrium with r<sup>2</sup> ≥0.8. Each of these regions was then further expanded to the nearest recombination hotspot. All genes in the Ensembl assembly GRCh37 were expanded to include 110 kb upstream and 40 kb downstream of the transcription start and end sites, respectively, to maximize capture of non-coding regulatory interactions, based upon previously published observations. Genes with windows calculated in this way found to be overlapping with any of the SNP windows were flagged for inclusion in the screen. In addition, each locus was examined individually, and in cases of gene deserts, unusually proximal recombination hotspots, or other unusual genomic structures, the SNP region was expanded to include additional genes nearby. This resulted in a total of 389 test genes, which were each targeted by 4–7 distinct shRNAs. Also included in the library were shRNAs targeting a set of 8 validated erythroid genes (<italic>GATA1, RPL5, RPS19, EPOR, ALAS2, CDAN1, SEC23B, ZFPM1</italic>). A pooled library of 2803 TRC clones was produced from the sequence-validated TRC shRNA library (<xref ref-type="bibr" rid="bib43">Moffat et al., 2006</xref>) and included shRNAs targeting control genes and essential genes.</p></sec><sec id="s4-2"><title>Pooled shRNA screening</title><p>Mobilized peripheral blood CD34<sup>+</sup> cells from three separate donors (7 ~ 11 * 10<sup>6</sup> cells per donor) were differentiated into erythroid cells using a three-stage system that has been previously described (<xref ref-type="bibr" rid="bib29">Hu et al., 2013</xref>). Cells were cultured using IMDM containing 2% human plasma, 3% human AB serum, 200 µg/ml human holo-transferrin, 3 IU/mL heparin, and 10 mg/mL insulin (base medium). During days 0 to 7, cells were supplemented with IL-3 (1 ng/mL), SCF (10 ng/ml), and EPO (3 IU/ml). On day 2 of this culture, cells were transduced with the pooled lentiviral shRNA library prepared by Broad Institute Genetic Perturbation Platform (1 ml of virus per 0.75 * 10<sup>6</sup> cells) by spinfection at 2000 rpm for 90 min with 6 µg/ml polybrene. During days 7 to 13, cells were supplemented with SCF and EPO only. After day 13, cells were supplemented with EPO alone and the holo-transferrin concentration was increased to 1 mg/ml. A minimum of 10 * 10<sup>6</sup> cells was re-plated at each time point to ensure appropriate library representation and prevent bottlenecks among the infected cells. Cell pellets were made from 20 ~ 80 * 10<sup>6</sup> cells at days 4, 6, 9, 12, 14, and 16. At the conclusion of the pooled screen, genomic DNA (gDNA) was extracted from the cell pellets using NucleoSpin Blood XL-Maxi kit (Clonetech) according to kit specifications. The shRNA-containing region was PCR amplified from the purified gDNA and barcoded using the following conditions: 0.5 μl P5 primer mix (100 μM), 10 μl P7 primer mix (5 μM), 8 μl dNTP mix, 1x ExTaq buffer, 1.5 μl of ExTaq DNA polymerase (Takara), and up to 10 μg genomic DNA in a total reaction volume of 100 μl. A total of 40 ~ 87.5 μg gDNA was used as template from each condition. Thermal cycler PCR conditions consisted of heating samples to 95°C for 5 min; 28 cycles of 95°C for 30 s, 53°C for 30 s, and 72°C for 20 s; and 72°C for 10 min. Equal amounts of samples were then mixed and purified using AMPure XP for PCR purification (Beckman Coulter). Samples were sequenced using a custom sequencing primer using standard Illumina conditions by the Broad Institute Genetic Perturbation Platform. Sequencing reads were deconvolved and hairpin counts were quantified for subsequent analysis by counting against the barcode reference using PoolQ</p><p>(<ext-link ext-link-type="uri" xlink:href="https://portals.broadinstitute.org/gpp/public/dir/download?dirpath=software&amp;filename=poolq-2.2.0-manual.pdf">https://portals.broadinstitute.org/gpp/public/dir/download?dirpath=software&amp;filename=poolq-2.2.0-manual.pdf</ext-link>).</p><p>P5 primer</p><p><bold>AATGATACGGCGACCACCGAGATCT</bold></p><p>ACACTCTTTCCCTACACGACGCTCTTCCGATCT[s]<bold>TCTTGTGGAAAGG*A*C*G*A</bold></p><p>A mix of P5 primers with stagger regions [s] of different length was used to maintain sequence diversity across the flow-cell.</p><p>P7 primer</p><p><bold>CAAGCAGAAGACGGCATACGAGAT</bold>NNNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT<bold>TCTACTATTCTTTCCCCTGCA*C*T*G*T</bold></p><p>Independently barcoded P7 primers was used for each condition.</p><p>NNNNNNNN – barcode region</p></sec><sec id="s4-3"><title>Analysis of the shRNA screen</title><p>A jupyter notebook, along with companion data files to reproduce the figures and analysis in this work, can be found at <ext-link ext-link-type="uri" xlink:href="https://github.com/sankaranlab/shRNA_screen">https://github.com/sankaranlab/shRNA_screen</ext-link> (<xref ref-type="bibr" rid="bib49">Nandakumar and McFarland, 2019</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/shRNA_screen">https://github.com/elifesciences-publications/shRNA_screen</ext-link>). To summarize, three separate donor primary CD34<sup>+</sup> cells populations were run as replicates in the shRNA screen. A pseudocount of 1 was added to all shRNA-encoding DNA count totals and these counts were subsequently normalized to counts per million (CPM) and log<sub>2</sub> transformed. A linear mixed model was constructed to fit fixed effects for each gene at each time point since transfection (t) using the log<sub>2</sub> fold change from initial hairpin counts as the response variable (<italic>y</italic>). A random effect was included to capture variations in efficacy and off-target effects for each shRNA (<italic>h</italic>) used to target a given gene that could accumulate over the course of the experiment. The resulting model, <italic>y ~ t + (0 + t|h)</italic>, was fit in R-3.4 using the lme4 package. Genes hits were called from the set of genes with β coefficient effect size &gt;0.1 and the Wald chi-square test adjusted q value &lt; 0.1. Enrichment of erythroid essential genes within the hit set was calculated by running 1 million permutations against the distribution of K562 essentiality for all genes included in the library, panels of genes nominated by sets of significant GWAS-associated lipid trait SNPs (<xref ref-type="bibr" rid="bib22">Global Lipids Genetics Consortium et al., 2013</xref>), and against all genes in the genome (Ensembl GRCh37p9). Coding variants and protein effects (i.e. missense or nonsense) were annotated based on the Variant Effect Predictor software (<ext-link ext-link-type="uri" xlink:href="https://www.ensembl.org/vep">https://www.ensembl.org/vep</ext-link>). Enrichment for identification of the included 5 ‘gold standard’ genes and for red blood cell trait-associated coding variants were each accomplished using identical permutation schemes. Expression of the hit genes in various cell states/stages of differentiation was derived from the cited datasets and permuted across all unique stages to determine stage-specific enrichment. The interaction network surrounding the 77 hits identified in the screen was generated in the latest version of STRING (10.5) and filtered for the purposes of display to only those nodes with at least one edge to another node among the hits. For the comparison with eQTL-based methods of hit identification, we used the whole blood summary statistics from GTEx and intersected them with genomic regions in linkage disequilibrium r<sup>2</sup> &gt;0.8 with the 75 sentinel SNPs from the van der Harst et al. study used to identify the library of genes targeted in the screen (see <xref ref-type="fig" rid="fig1">Figure 1A</xref>). These regions were padded to a fixed 100 kb, as many of the regions were small. This yielded 139 genes that one could argue would be nominated on an eQTL-basis from the total pool of 8661 genes with a whole blood eQTL. We performed a Fisher’s exact test on the contingency table comparing hits from our method of nomination with the set of eQTLs and eQTL-nominated genes. There were 35 hits (of the 77 total in our screen) present among the whole eQTL set, but 0 hits found among the 139 genes nominated by using eQTLs from whole blood. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 06/01/18.</p></sec><sec id="s4-4"><title>RNA-Seq</title><p>Stage matched CD71<sup>+</sup>/ CD235a<sup>+</sup> cells derived from CD34<sup>+</sup> HSPCs infected with SF3A2 sh3, sh4 and shLUC were FACS sorted at day 8 of erythroid differentiation. RNA was isolated using a RNAqueous Micro kit (Invitrogen) according to the manufacturer’s instructions. DNase digestion was performed before RNA was quantified using a Qubit RNA HS Assay kit (Invitrogen). 1–10 ng of RNA were used as input to a modified SMART-seq2 (<xref ref-type="bibr" rid="bib54">Picelli et al., 2014</xref>) protocol and after reverse transcription, 8–9 cycles of PCR were used to amplify transcriptome library. Quality of whole transcriptome libraries was validated using a High Sensitivity DNA Chip run on a Bioanalyzer 2100 system (Agilent), followed by library preparation using the Nextera XT kit (Illumina) and custom index primers according to the manufacturer’s instructions. Final libraries were quantified using a Qubit dsDNA HS Assay kit (Invitrogen) and a high sensitivity DNA chip run on a Bioanalyzer 2100 system (Agilent). All libraries were sequenced using Nextseq High Output Cartridge kits and a Nextseq 500 sequencer (Illumina). Libraries were sequenced using 2 × 38 bp paired end reads.</p></sec><sec id="s4-5"><title>RNA-seq differential expression analysis</title><p>For differential expression analysis, paired end sequencing reads from our SF3A2 shRNA knockdown experiments and obtained from the SF3B1 mutant datasets (<xref ref-type="bibr" rid="bib51">Obeng et al., 2016</xref>) were quantified using Salmon version 0.11.1 (<xref ref-type="bibr" rid="bib52">Patro et al., 2017</xref>) with default parameters and an index constructed from Gencode annotations version 28. Differential expression of quantified counts was calculated using DESeq2 (<xref ref-type="bibr" rid="bib38">Love et al., 2014</xref>) in R-3.4. Enrichment for functions and components of the cell among the differentially expressed gene sets were quantified using GOrilla (<xref ref-type="bibr" rid="bib14">Eden et al., 2007</xref>; <xref ref-type="bibr" rid="bib15">Eden et al., 2009</xref>).</p></sec><sec id="s4-6"><title>RNA-seq differential splicing analysis</title><p>Paired end sequencing reads from our SF3A2 shRNA knockdown experiments and obtained from the cited SF3B1 mutant datasets were aligned using STAR version 2.5.2 in two-pass mode. Differential splicing was quantified using MISO version 0.5.4 in Python 2.7 using the instructions and annotation files provided with the package (<xref ref-type="bibr" rid="bib33">Katz et al., 2010</xref>). The software’s default cutoff of Bayes factor of 10 or greater was used to call differential splice forms.</p></sec><sec id="s4-7"><title>Analysis of hemoglobin levels for MDS patients with or without SF3A2 mutations</title><p>Genotyped MDS patient hemoglobin level measurements were obtained from the laboratory of J. Maciejewski. 1000GENOMES phase three data were used to find a SNP encoded in whole-exome sequencing data (rs25672) in high LD (r<sup>2</sup> = 0.737675) with the SF3A2-associated sentinel SNP (rs2159213). An ordinary least squares linear regression was used to fit the patient hemoglobin levels to the number of SF3A2 minor alleles present in each patient (log likelihood ratio test p=0.140).</p></sec><sec id="s4-8"><title>Phosphorylated STAT5 assessment with intracellular flow cytometry</title><p>UT-7/EPO cells were cultured in DMEM medium supplemented with 10% Fetal Bovine Serum and 2 U/mL EPO. 5 days post-infection with TFR2 shRNAs, UT-7/EPO cells were cytokine starved overnight. On the next day, cells were treated with EPO in a dose dependent manner ((0 U/mL, 0.002 U/mL, 0.02 U/mL, 0.2 U/mL, 2 U/mL, 20 U/mL and 200 U/mL) and incubated 37°C for 30 min. Alternatively the cells were treated with 2 U/ml EPO in a time dependent manner (15, 30, 60, 120,180 min). Treated cells were gently mixed with pre-warmed Fixation Buffer (BD Bioscience) at 37°C for 10 min to fix cells. To permeabilize cells for intracellular staining, cells were resuspended in pre-chilled Perm Buffer III (BD Bioscience) for 30 min at 4°C. After three washes with 3% FBS in PBS, samples were stained either with Alexa Fluor-647 Mouse Anti-phospho-STAT5 (pY694; 1:20 dilution) for 1 hr in the dark at room temperature. A BD Accuri C6 Cytometer (BD Bioscience) was used to acquire mean fluorescent intensity (MFI) of phospho-STAT5-Alexa Fluor 647. The MFI of phospho-STAT5-Alexa Fluor 647 of gated single cells was calculated using FlowJo (version 10.0.8r1). Unstimulated UT7/EPO cells were used as a negative control.</p></sec><sec id="s4-9"><title>May-Grünwald-Giemsa staining</title><p>Approximately 50,000–200,000 cells were harvested, washed once at 300 x g for 5 min, resuspended in 200 µL FACS buffer and spun onto poly-L-lysine coated glass slides (Sigma Aldrich) with a Shandon 4 (Thermo Fisher) cytocentrifuge at 300 rpm for 4 min. Visibly dry slides were stained with May-Grünwald solution for 5 min, rinsed four times for each 30 s in H2O, transferred to Giemsa solution for 15 min and washed as described above. Slides were dried overnight and mounted with coverslip. All images were taken with AxioVision software (Zeiss) at 100 x magnification.</p></sec><sec id="s4-10"><title>Mouse erythroid differentiation culture</title><p>Bone marrow cells that were isolated from <italic>Sf3b1</italic><sup>K700E +/-</sup> mice and littermate controls were lineage depleted using the Lineage Cell Depletion Kit, mouse (Miltenyi Biotech) according to manufacturer’s protocols. Lineage negative cells were immediately transduced with lentiviral shRNAs targeting SF3A2 or controls (MOI −90) by spinfection at 2000 rpm for 90 min. The cells were cultured in erythroid maintenance medium (StemSpan-SFEM; StemCell Technologies) supplemented with 100 ng/mL recombinant mouse stem cell factor (SCF) (R&amp;D Systems), 40 ng/mL recombinant mouse IGF1 (R&amp;D Systems), 100 nM dexamethasone (Sigma), and 2 U/mL erythropoietin (Amgen) and cultured at 37°C for 36 hr. Following this, the cells were cultured for another 48 hr in erythroid differentiation medium (Iscove modified Dulbecco’s medium containing 15% (vol/vol) FBS (Stemcell), 1% detoxified BSA (Stemcell), 500 μg/mL holo-transferrin (Sigma-Aldrich), 0.5 U/mL Epoetin (Epo; Amgen), 10 μg/mL recombinant human insulin (Sigma-Aldrich), and 2 mM L-glutamine (Invitrogen)) at 37°C.</p></sec><sec id="s4-11"><title>Flow cytometry analyses and antibodies</title><p>All flow cytometry data were acquired using either using LSR II SORP or LSR Fortessa flow cytometers (BD Biosciences). All staining was carried out in FACS buffer (2% FBS in PBS) for 30 min on ice unless otherwise described. The following antibodies were used anti-human CD235a-APC (eBioscience, Clone HIR2), anti-human CD71-FITC (eBioscience, Clone OKT9), anti-human CD71-PEcy7 (eBioscience, Clone OKT9), ant-human CD49d-PE (Miltenyi, Clone MZ18-24A9), anti-human CD41a-PE (eBioscience, Clone HIP8), anti-human CD11b-PE (eBioscience, Clone ICRF44), anti-mouse Ter119-APC (eBioscience, Clone TER119), anti-mouse CD71-PE (eBioscience, Clone R17217) and Alexa Fluor-647 anti-phospho STAT5 (pY694) (BD Bioscience Cat#: 612599). Hoechst 33342 (Life Technologies, H1399) was used to visualize nuclei.</p></sec><sec id="s4-12"><title>shRNA sequences</title><p>The following lentiviral shRNA constructs were generated in Polymerase III based shRNA backbone pLKO.1-puro (Sigma Aldrich).</p><p>shLUC</p><p>5’-CCGGCGCTGAGTACTTCGAAATGTCCTCGAGGACATTTCGAAGTACTCAGCGTTTTTG-3’</p><p>TFR2 sh1</p><p>5'-CCGGGCCAGATCACTACGTTGTCATCTCGAGATGACAACGTAGTGATCTGGCTTTTTG-3</p><p>TFR2 sh2</p><p>5'-CCGGCAACAACATCTTCGGCTGCATCTCGAGATGCAGCCGAAGATGTTGTTGTTTTTG-3'</p><p>SF3A2 sh1 (human)</p><p>5'-CCGGCTACGAGACCATTGCCTTCAACTCGAGTTGAAGGCAATGGTCTCGTAGTTTTT-3</p><p>SF3A2 sh2 (human)</p><p>5'-CCGGCCTGGGCTCCTATGAATGCAACTCGAGTTGCATTCATAGGAGCCCAGGTTTTT-3'</p><p>SF3A2 sh3 (human)</p><p>5'-CCGGCAAAGTGACCAAGCAGAGAGACTCGAGTCTCTCTGCTTGGTCACTTTGTTTTT-3</p><p>SF3A2 sh4 (human)</p><p>5'-CCGGACATCAACAAGGACCCGTACTCTCGAGAGTACGGGTCCTTGTTGATGTTTTTT-3'</p><p>The following lentiviral shRNA constructs were generated in Polymerase II based mir30 shRNA backbone developed in the lab SFFV-Venus-mir30 shRNA backbone.</p><p>shNT(non-targeting)</p><p>5’_TGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGTAAGTAGTGAAGCCACAGATGTACTTACTCTCGCCCAAGCGAGAGTGCCTACTGCCTCGGA_3’</p><p><italic>Sf3a2</italic> sh1 (mouse)</p><p>5’_TGCTGTTGACAGTGAGCGCGGAGGTGAAGAAGTTTGTGAATAGTGAAGCCACAGATGTATTCACAAACTTCTTCACCTCCATGCCTACTGCCTCGGA_3’</p><p><italic>Sf3a2</italic> sh2 (mouse)</p><p>5’_TGCTGTTGACAGTGAGCGACCACCGTTTCATGTCTGCTTATAGTGAAGCCACAGATGTATAAGCAGACATGAAACGGTGGCTGCCTACTGCCTCGGA_3’</p><p><italic>Sf3a2</italic> sh3 (mouse)</p><p>5’_TGCTGTTGACAGTGAGCGATCCTGCCTTGAGCCTATTAAATAGTGAAGCCACAGATGTATTTAATAGGCTCAAGGCAGGACTGCCTACTGCCTCGGA_3’</p><p><italic>Sf3a2</italic> sh4 (mouse)</p><p>5’_TGCTGTTGACAGTGAGCGACCACTGGAACAGAGAAACCAATAGTGAAGCCACAGATGTATTGGTTTCTCTGTTCCAGTGGGTGCCTACTGCCTCGGA_3’</p><p><italic>Sf3a2</italic> sh5 (mouse)</p><p>5’_TGCTGTTGACAGTGAGCGATGGAGGTGAAGAAGTTTGTGATAGTGAAGCCACAGATGTATCACAAACTTCTTCACCTCCACTGCCTACTGCCTCGGA_3’</p><sec id="s4-12-1"><title>sgRNA sequences</title><p>The following sgRNA sequences targeting a variant in the Duffy promoter were cloned into SpCas9 and KRAB-dcas9 constructs.</p><p>Duffy sgRNA 3: 5’-GGCCCGCAGACAGAAGGGCT-3’</p><p>Duffy sgRNA 5: 5’-GGGCCATCAGGTTCTGGGCA-3’</p><p>Control sgRNA: 5’-ATCGCGAGGACCCGTTCCGCC-3’</p></sec><sec id="s4-12-2"><title>qPCR primers</title><p><italic>TFR2</italic> Fwd: 5'-ATCCTTCCCTCTTCCCTCCC-3'</p><p><italic>TFR2</italic> Rev: 5'-CCATCCAGCCACATGGTTCT-3</p><p><italic>SF3A2</italic> Fwd: 5'-CCTGAGAAGGTCAAGGTGGA-3'</p><p><italic>SF3A2</italic> Rev: 5'-CTCCGAGTCTCTCTGCTTGG-3'</p></sec></sec><sec id="s4-13"><title>Western blot antibodies</title><p>Anti-GAPDH (Santa Cruz Biotechnology, sc-32233); anti-TFR2 (Santa Cruz Biotechnology, sc- sc-32271); anti-SF3A2 (Santa Cruz Biotechnology, sc-390444).</p></sec><sec id="s4-14"><title>Source data</title><p>Important data associated with figures in the manuscript are included below. For a full set of datasets and resources used in the analyses, please see the companion GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/sankaranlab/shRNA_screen">https://github.com/sankaranlab/shRNA_screen</ext-link>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank members of the Sankaran laboratory for valuable comments and suggestions on these studies. This work was supported by the National Institutes of Health grants R01 DK103794 and R33 HL120791, as well as the New York Stem Cell Foundation (to VGS). VGS is a New York Stem Cell Foundation-Robertson Investigator.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Validation, Investigation, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con14"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.44080.028</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-44080-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>1000 Genomes human variation dataset: The 1000 Genomes Project Consortium. (2015) Recombinant hotspots access at: <ext-link ext-link-type="uri" xlink:href="ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/pilot_data/technical/reference/">ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/pilot_data/technical/reference/</ext-link>. Phase 1 data (for PLINK) accessed at: <ext-link ext-link-type="uri" xlink:href="https://www.cog-genomics.org/plink/1.9/resources">https://www.cog-genomics.org/plink/1.9/resources</ext-link>. Phase 3 data accessed at: <ext-link ext-link-type="uri" xlink:href="http://www.internationalgenome.org/category/phase-3/">http://www.internationalgenome.org/category/phase-3/</ext-link>. Pooled screen abundance data for shRNA targeting red blood cell trait GWAS-nominated genes during the course of in vitro differentiation of human CD34+ cells (SK Nandakumar, SK McFarland et al., 2019) is available on the project's companion GitHub repository: <ext-link ext-link-type="uri" xlink:href="https://github.com/sankaranlab/shRNA_screen/tree/master/ref/shref.csv">https://github.com/sankaranlab/shRNA_screen/tree/master/ref/shref.csv</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/shRNA_screen">https://github.com/elifesciences-publications/shRNA_screen</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation id="dataset5" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Satish</surname><given-names>K Nandakumar</given-names></name><name><surname>Sean</surname><given-names>K McFarland</given-names></name><name><surname>Laura</surname><given-names>M Mateyka</given-names></name><name><surname>Caleb</surname><given-names>A Lareau</given-names></name><name><surname>Leif</surname><given-names>S Ludwig</given-names></name><name><surname>Vijay</surname><given-names>G Sankaran</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Effects of shRNA knockdown of SF3A2 on splicing during human erythropoiesis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129603">GSE129603</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Hale</surname><given-names>JP</given-names></name><name><surname>Jaffray</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Hillyer</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Kinet</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name><name><surname>Narla</surname><given-names>M</given-names></name><name><surname>Narla</surname><given-names>A</given-names></name><name><surname>Blanc</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Human adult and fetal erythropoiesis gene expression</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107218">GSE107218</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Corces</surname><given-names>MR</given-names></name><name><surname>Buenrostro</surname><given-names>JD</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Greenside</surname><given-names>PG</given-names></name><name><surname>Chan</surname><given-names>SM</given-names></name><name><surname>Koenig</surname><given-names>JL</given-names></name><name><surname>Snyder</surname><given-names>MP</given-names></name><name><surname>Pritchard</surname><given-names>JK</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Greenleaf</surname><given-names>W</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Human hematopoietic lineage gene expression</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74912">GSE74912</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Global</surname><given-names>Lipids Genetics Consortium</given-names></name></person-group><year iso-8601-date="2013">2013</year><data-title>SNP sets identified by GWAS of LDL, HDL, and triglyceride traits</data-title><source>Center for Statistical Genetics</source><pub-id assigning-authority="other" pub-id-type="archive" xlink:href="http://csg.sph.umich.edu/willer/public/lipids2013/">lipids2013</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Obeng</surname><given-names>EA</given-names></name><name><surname>Chappell</surname><given-names>RJ</given-names></name><name><surname>Seiler</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>MC</given-names></name><name><surname>Campagna</surname><given-names>DR</given-names></name><name><surname>Schmidt</surname><given-names>PJ</given-names></name><name><surname>Schneider</surname><given-names>RK</given-names></name><name><surname>Lord</surname><given-names>AM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gambe</surname><given-names>RG</given-names></name><name><surname>McConkey</surname><given-names>ME</given-names></name><name><surname>Ali</surname><given-names>AM</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Buonamici</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>PG</given-names></name><name><surname>Mullally</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Fleming</surname><given-names>MD</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Effects of SF3B1 mutants on splicing in human erythropoiesis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85712">GSE85712</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artuso</surname> <given-names>I</given-names></name><name><surname>Lidonnici</surname> <given-names>MR</given-names></name><name><surname>Altamura</surname> <given-names>S</given-names></name><name><surname>Mandelli</surname> <given-names>G</given-names></name><name><surname>Pettinato</surname> <given-names>M</given-names></name><name><surname>Muckenthaler</surname> <given-names>MU</given-names></name><name><surname>Silvestri</surname> <given-names>L</given-names></name><name><surname>Ferrari</surname> <given-names>G</given-names></name><name><surname>Camaschella</surname> <given-names>C</given-names></name><name><surname>Nai</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model</article-title><source>Blood</source><volume>132</volume><fpage>2286</fpage><lpage>2297</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-05-852277</pub-id><pub-id pub-id-type="pmid">30209118</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astle</surname> <given-names>WJ</given-names></name><name><surname>Elding</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>T</given-names></name><name><surname>Allen</surname> <given-names>D</given-names></name><name><surname>Ruklisa</surname> <given-names>D</given-names></name><name><surname>Mann</surname> <given-names>AL</given-names></name><name><surname>Mead</surname> <given-names>D</given-names></name><name><surname>Bouman</surname> <given-names>H</given-names></name><name><surname>Riveros-Mckay</surname> <given-names>F</given-names></name><name><surname>Kostadima</surname> <given-names>MA</given-names></name><name><surname>Lambourne</surname> <given-names>JJ</given-names></name><name><surname>Sivapalaratnam</surname> <given-names>S</given-names></name><name><surname>Downes</surname> <given-names>K</given-names></name><name><surname>Kundu</surname> <given-names>K</given-names></name><name><surname>Bomba</surname> <given-names>L</given-names></name><name><surname>Berentsen</surname> <given-names>K</given-names></name><name><surname>Bradley</surname> <given-names>JR</given-names></name><name><surname>Daugherty</surname> <given-names>LC</given-names></name><name><surname>Delaneau</surname> <given-names>O</given-names></name><name><surname>Freson</surname> <given-names>K</given-names></name><name><surname>Garner</surname> <given-names>SF</given-names></name><name><surname>Grassi</surname> <given-names>L</given-names></name><name><surname>Guerrero</surname> <given-names>J</given-names></name><name><surname>Haimel</surname> <given-names>M</given-names></name><name><surname>Janssen-Megens</surname> <given-names>EM</given-names></name><name><surname>Kaan</surname> <given-names>A</given-names></name><name><surname>Kamat</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>B</given-names></name><name><surname>Mandoli</surname> <given-names>A</given-names></name><name><surname>Marchini</surname> <given-names>J</given-names></name><name><surname>Martens</surname> <given-names>JHA</given-names></name><name><surname>Meacham</surname> <given-names>S</given-names></name><name><surname>Megy</surname> <given-names>K</given-names></name><name><surname>O'Connell</surname> <given-names>J</given-names></name><name><surname>Petersen</surname> <given-names>R</given-names></name><name><surname>Sharifi</surname> <given-names>N</given-names></name><name><surname>Sheard</surname> <given-names>SM</given-names></name><name><surname>Staley</surname> <given-names>JR</given-names></name><name><surname>Tuna</surname> <given-names>S</given-names></name><name><surname>van der Ent</surname> <given-names>M</given-names></name><name><surname>Walter</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>SY</given-names></name><name><surname>Wheeler</surname> <given-names>E</given-names></name><name><surname>Wilder</surname> <given-names>SP</given-names></name><name><surname>Iotchkova</surname> <given-names>V</given-names></name><name><surname>Moore</surname> <given-names>C</given-names></name><name><surname>Sambrook</surname> <given-names>J</given-names></name><name><surname>Stunnenberg</surname> <given-names>HG</given-names></name><name><surname>Di Angelantonio</surname> <given-names>E</given-names></name><name><surname>Kaptoge</surname> <given-names>S</given-names></name><name><surname>Kuijpers</surname> <given-names>TW</given-names></name><name><surname>Carrillo-de-Santa-Pau</surname> <given-names>E</given-names></name><name><surname>Juan</surname> <given-names>D</given-names></name><name><surname>Rico</surname> <given-names>D</given-names></name><name><surname>Valencia</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Ge</surname> <given-names>B</given-names></name><name><surname>Vasquez</surname> <given-names>L</given-names></name><name><surname>Kwan</surname> <given-names>T</given-names></name><name><surname>Garrido-Martín</surname> <given-names>D</given-names></name><name><surname>Watt</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Guigo</surname> <given-names>R</given-names></name><name><surname>Beck</surname> <given-names>S</given-names></name><name><surname>Paul</surname> <given-names>DS</given-names></name><name><surname>Pastinen</surname> <given-names>T</given-names></name><name><surname>Bujold</surname> <given-names>D</given-names></name><name><surname>Bourque</surname> <given-names>G</given-names></name><name><surname>Frontini</surname> <given-names>M</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Roberts</surname> <given-names>DJ</given-names></name><name><surname>Ouwehand</surname> <given-names>WH</given-names></name><name><surname>Butterworth</surname> <given-names>AS</given-names></name><name><surname>Soranzo</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The allelic landscape of human blood cell trait variation and links to common complex disease</article-title><source>Cell</source><volume>167</volume><fpage>1415</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.10.042</pub-id><pub-id pub-id-type="pmid">27863252</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basak</surname> <given-names>A</given-names></name><name><surname>Hancarova</surname> <given-names>M</given-names></name><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Balci</surname> <given-names>TB</given-names></name><name><surname>Trkova</surname> <given-names>M</given-names></name><name><surname>Pelisek</surname> <given-names>M</given-names></name><name><surname>Vlckova</surname> <given-names>M</given-names></name><name><surname>Muzikova</surname> <given-names>K</given-names></name><name><surname>Cermak</surname> <given-names>J</given-names></name><name><surname>Trka</surname> <given-names>J</given-names></name><name><surname>Dyment</surname> <given-names>DA</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Sedlacek</surname> <given-names>Z</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations</article-title><source>Journal of Clinical Investigation</source><volume>125</volume><fpage>2363</fpage><lpage>2368</lpage><pub-id pub-id-type="doi">10.1172/JCI81163</pub-id><pub-id pub-id-type="pmid">25938782</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname> <given-names>V</given-names></name><name><surname>Stenbuck</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Identification and partial purification of ankyrin, the high affinity membrane attachment site for human erythrocyte spectrin</article-title><source>The Journal of Biological Chemistry</source><volume>254</volume><fpage>2533</fpage><lpage>2541</lpage><pub-id pub-id-type="pmid">372182</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname> <given-names>EA</given-names></name><name><surname>Li</surname> <given-names>YI</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An expanded view of complex traits: from polygenic to omnigenic</article-title><source>Cell</source><volume>169</volume><fpage>1177</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.038</pub-id><pub-id pub-id-type="pmid">28622505</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canver</surname> <given-names>MC</given-names></name><name><surname>Smith</surname> <given-names>EC</given-names></name><name><surname>Sher</surname> <given-names>F</given-names></name><name><surname>Pinello</surname> <given-names>L</given-names></name><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Shalem</surname> <given-names>O</given-names></name><name><surname>Chen</surname> <given-names>DD</given-names></name><name><surname>Schupp</surname> <given-names>PG</given-names></name><name><surname>Vinjamur</surname> <given-names>DS</given-names></name><name><surname>Garcia</surname> <given-names>SP</given-names></name><name><surname>Luc</surname> <given-names>S</given-names></name><name><surname>Kurita</surname> <given-names>R</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Fujiwara</surname> <given-names>Y</given-names></name><name><surname>Maeda</surname> <given-names>T</given-names></name><name><surname>Yuan</surname> <given-names>GC</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Bauer</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis</article-title><source>Nature</source><volume>527</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/nature15521</pub-id><pub-id pub-id-type="pmid">26375006</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>CC</given-names></name><name><surname>Chow</surname> <given-names>CC</given-names></name><name><surname>Tellier</surname> <given-names>LC</given-names></name><name><surname>Vattikuti</surname> <given-names>S</given-names></name><name><surname>Purcell</surname> <given-names>SM</given-names></name><name><surname>Lee</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Second-generation PLINK: rising to the challenge of larger and richer datasets</article-title><source>GigaScience</source><volume>4</volume><pub-id pub-id-type="doi">10.1186/s13742-015-0047-8</pub-id><pub-id pub-id-type="pmid">25722852</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Zheng</surname> <given-names>K</given-names></name><name><surname>Shalem</surname> <given-names>O</given-names></name><name><surname>Lee</surname> <given-names>K</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name><name><surname>Scott</surname> <given-names>DA</given-names></name><name><surname>Song</surname> <given-names>J</given-names></name><name><surname>Pan</surname> <given-names>JQ</given-names></name><name><surname>Weissleder</surname> <given-names>R</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Sharp</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis</article-title><source>Cell</source><volume>160</volume><fpage>1246</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.02.038</pub-id><pub-id pub-id-type="pmid">25748654</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium</collab><name><surname>Papaemmanuil</surname> <given-names>E</given-names></name><name><surname>Cazzola</surname> <given-names>M</given-names></name><name><surname>Boultwood</surname> <given-names>J</given-names></name><name><surname>Malcovati</surname> <given-names>L</given-names></name><name><surname>Vyas</surname> <given-names>P</given-names></name><name><surname>Bowen</surname> <given-names>D</given-names></name><name><surname>Pellagatti</surname> <given-names>A</given-names></name><name><surname>Wainscoat</surname> <given-names>JS</given-names></name><name><surname>Hellstrom-Lindberg</surname> <given-names>E</given-names></name><name><surname>Gambacorti-Passerini</surname> <given-names>C</given-names></name><name><surname>Godfrey</surname> <given-names>AL</given-names></name><name><surname>Rapado</surname> <given-names>I</given-names></name><name><surname>Cvejic</surname> <given-names>A</given-names></name><name><surname>Rance</surname> <given-names>R</given-names></name><name><surname>McGee</surname> <given-names>C</given-names></name><name><surname>Ellis</surname> <given-names>P</given-names></name><name><surname>Mudie</surname> <given-names>LJ</given-names></name><name><surname>Stephens</surname> <given-names>PJ</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>Massie</surname> <given-names>CE</given-names></name><name><surname>Tarpey</surname> <given-names>PS</given-names></name><name><surname>Varela</surname> <given-names>I</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Davies</surname> <given-names>HR</given-names></name><name><surname>Shlien</surname> <given-names>A</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Hinton</surname> <given-names>J</given-names></name><name><surname>Butler</surname> <given-names>AP</given-names></name><name><surname>Teague</surname> <given-names>JW</given-names></name><name><surname>Baxter</surname> <given-names>EJ</given-names></name><name><surname>Score</surname> <given-names>J</given-names></name><name><surname>Galli</surname> <given-names>A</given-names></name><name><surname>Della Porta</surname> <given-names>MG</given-names></name><name><surname>Travaglino</surname> <given-names>E</given-names></name><name><surname>Groves</surname> <given-names>M</given-names></name><name><surname>Tauro</surname> <given-names>S</given-names></name><name><surname>Munshi</surname> <given-names>NC</given-names></name><name><surname>Anderson</surname> <given-names>KC</given-names></name><name><surname>El-Naggar</surname> <given-names>A</given-names></name><name><surname>Fischer</surname> <given-names>A</given-names></name><name><surname>Mustonen</surname> <given-names>V</given-names></name><name><surname>Warren</surname> <given-names>AJ</given-names></name><name><surname>Cross</surname> <given-names>NC</given-names></name><name><surname>Green</surname> <given-names>AR</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts</article-title><source>The New England Journal of Medicine</source><volume>365</volume><fpage>1384</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103283</pub-id><pub-id pub-id-type="pmid">21995386</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claussnitzer</surname> <given-names>M</given-names></name><name><surname>Dankel</surname> <given-names>SN</given-names></name><name><surname>Kim</surname> <given-names>KH</given-names></name><name><surname>Quon</surname> <given-names>G</given-names></name><name><surname>Meuleman</surname> <given-names>W</given-names></name><name><surname>Haugen</surname> <given-names>C</given-names></name><name><surname>Glunk</surname> <given-names>V</given-names></name><name><surname>Sousa</surname> <given-names>IS</given-names></name><name><surname>Beaudry</surname> <given-names>JL</given-names></name><name><surname>Puviindran</surname> <given-names>V</given-names></name><name><surname>Abdennur</surname> <given-names>NA</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Svensson</surname> <given-names>PA</given-names></name><name><surname>Hsu</surname> <given-names>YH</given-names></name><name><surname>Drucker</surname> <given-names>DJ</given-names></name><name><surname>Mellgren</surname> <given-names>G</given-names></name><name><surname>Hui</surname> <given-names>CC</given-names></name><name><surname>Hauner</surname> <given-names>H</given-names></name><name><surname>Kellis</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>FTO obesity variant circuitry and Adipocyte Browning in humans</article-title><source>New England Journal of Medicine</source><volume>373</volume><fpage>895</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1502214</pub-id><pub-id pub-id-type="pmid">26287746</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corces</surname> <given-names>MR</given-names></name><name><surname>Buenrostro</surname> <given-names>JD</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Greenside</surname> <given-names>PG</given-names></name><name><surname>Chan</surname> <given-names>SM</given-names></name><name><surname>Koenig</surname> <given-names>JL</given-names></name><name><surname>Snyder</surname> <given-names>MP</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name><name><surname>Kundaje</surname> <given-names>A</given-names></name><name><surname>Greenleaf</surname> <given-names>WJ</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution</article-title><source>Nature Genetics</source><volume>48</volume><fpage>1193</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1038/ng.3646</pub-id><pub-id pub-id-type="pmid">27526324</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>DBA Group of Société d'Hématologie et d'Immunologie Pédiatrique-SHIP</collab><name><surname>Moniz</surname> <given-names>H</given-names></name><name><surname>Gastou</surname> <given-names>M</given-names></name><name><surname>Leblanc</surname> <given-names>T</given-names></name><name><surname>Hurtaud</surname> <given-names>C</given-names></name><name><surname>Crétien</surname> <given-names>A</given-names></name><name><surname>Lécluse</surname> <given-names>Y</given-names></name><name><surname>Raslova</surname> <given-names>H</given-names></name><name><surname>Larghero</surname> <given-names>J</given-names></name><name><surname>Croisille</surname> <given-names>L</given-names></name><name><surname>Faubladier</surname> <given-names>M</given-names></name><name><surname>Bluteau</surname> <given-names>O</given-names></name><name><surname>Lordier</surname> <given-names>L</given-names></name><name><surname>Tchernia</surname> <given-names>G</given-names></name><name><surname>Vainchenker</surname> <given-names>W</given-names></name><name><surname>Mohandas</surname> <given-names>N</given-names></name><name><surname>Da Costa</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro</article-title><source>Cell Death &amp; Disease</source><volume>3</volume><elocation-id>e356</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2012.88</pub-id><pub-id pub-id-type="pmid">22833095</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eden</surname> <given-names>E</given-names></name><name><surname>Lipson</surname> <given-names>D</given-names></name><name><surname>Yogev</surname> <given-names>S</given-names></name><name><surname>Yakhini</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Discovering motifs in ranked lists of DNA sequences</article-title><source>PLoS Computational Biology</source><volume>3</volume><elocation-id>e39</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0030039</pub-id><pub-id pub-id-type="pmid">17381235</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eden</surname> <given-names>E</given-names></name><name><surname>Navon</surname> <given-names>R</given-names></name><name><surname>Steinfeld</surname> <given-names>I</given-names></name><name><surname>Lipson</surname> <given-names>D</given-names></name><name><surname>Yakhini</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists</article-title><source>BMC Bioinformatics</source><volume>10</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-10-48</pub-id><pub-id pub-id-type="pmid">19192299</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forejtnikovà</surname> <given-names>H</given-names></name><name><surname>Vieillevoye</surname> <given-names>M</given-names></name><name><surname>Zermati</surname> <given-names>Y</given-names></name><name><surname>Lambert</surname> <given-names>M</given-names></name><name><surname>Pellegrino</surname> <given-names>RM</given-names></name><name><surname>Guihard</surname> <given-names>S</given-names></name><name><surname>Gaudry</surname> <given-names>M</given-names></name><name><surname>Camaschella</surname> <given-names>C</given-names></name><name><surname>Lacombe</surname> <given-names>C</given-names></name><name><surname>Roetto</surname> <given-names>A</given-names></name><name><surname>Mayeux</surname> <given-names>P</given-names></name><name><surname>Verdier</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis</article-title><source>Blood</source><volume>116</volume><fpage>5357</fpage><lpage>5367</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-281360</pub-id><pub-id pub-id-type="pmid">20826723</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulco</surname> <given-names>CP</given-names></name><name><surname>Munschauer</surname> <given-names>M</given-names></name><name><surname>Anyoha</surname> <given-names>R</given-names></name><name><surname>Munson</surname> <given-names>G</given-names></name><name><surname>Grossman</surname> <given-names>SR</given-names></name><name><surname>Perez</surname> <given-names>EM</given-names></name><name><surname>Kane</surname> <given-names>M</given-names></name><name><surname>Cleary</surname> <given-names>B</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Engreitz</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Systematic mapping of functional enhancer-promoter connections with CRISPR interference</article-title><source>Science</source><volume>354</volume><fpage>769</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1126/science.aag2445</pub-id><pub-id pub-id-type="pmid">27708057</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galarneau</surname> <given-names>G</given-names></name><name><surname>Palmer</surname> <given-names>CD</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Lettre</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation</article-title><source>Nature Genetics</source><volume>42</volume><fpage>1049</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1038/ng.707</pub-id><pub-id pub-id-type="pmid">21057501</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazda</surname> <given-names>HT</given-names></name><name><surname>Preti</surname> <given-names>M</given-names></name><name><surname>Sheen</surname> <given-names>MR</given-names></name><name><surname>O'Donohue</surname> <given-names>MF</given-names></name><name><surname>Vlachos</surname> <given-names>A</given-names></name><name><surname>Davies</surname> <given-names>SM</given-names></name><name><surname>Kattamis</surname> <given-names>A</given-names></name><name><surname>Doherty</surname> <given-names>L</given-names></name><name><surname>Landowski</surname> <given-names>M</given-names></name><name><surname>Buros</surname> <given-names>C</given-names></name><name><surname>Ghazvinian</surname> <given-names>R</given-names></name><name><surname>Sieff</surname> <given-names>CA</given-names></name><name><surname>Newburger</surname> <given-names>PE</given-names></name><name><surname>Niewiadomska</surname> <given-names>E</given-names></name><name><surname>Matysiak</surname> <given-names>M</given-names></name><name><surname>Glader</surname> <given-names>B</given-names></name><name><surname>Atsidaftos</surname> <given-names>E</given-names></name><name><surname>Lipton</surname> <given-names>JM</given-names></name><name><surname>Gleizes</surname> <given-names>PE</given-names></name><name><surname>Beggs</surname> <given-names>AH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-blackfan anemia</article-title><source>Human Mutation</source><volume>33</volume><fpage>1037</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1002/humu.22081</pub-id><pub-id pub-id-type="pmid">22431104</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giani</surname> <given-names>FC</given-names></name><name><surname>Fiorini</surname> <given-names>C</given-names></name><name><surname>Wakabayashi</surname> <given-names>A</given-names></name><name><surname>Ludwig</surname> <given-names>LS</given-names></name><name><surname>Salem</surname> <given-names>RM</given-names></name><name><surname>Jobaliya</surname> <given-names>CD</given-names></name><name><surname>Regan</surname> <given-names>SN</given-names></name><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Liang</surname> <given-names>G</given-names></name><name><surname>Steinberg-Shemer</surname> <given-names>O</given-names></name><name><surname>Guo</surname> <given-names>MH</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Tong</surname> <given-names>W</given-names></name><name><surname>Brugnara</surname> <given-names>C</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Weiss</surname> <given-names>MJ</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name><name><surname>Chou</surname> <given-names>ST</given-names></name><name><surname>French</surname> <given-names>DL</given-names></name><name><surname>Musunuru</surname> <given-names>K</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeted application of human genetic variation can improve red blood cell production from stem cells</article-title><source>Cell Stem Cell</source><volume>18</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.09.015</pub-id><pub-id pub-id-type="pmid">26607381</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glick</surname> <given-names>BS</given-names></name><name><surname>Rothman</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Possible role for fatty acyl-coenzyme A in intracellular protein transport</article-title><source>Nature</source><volume>326</volume><fpage>309</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/326309a0</pub-id><pub-id pub-id-type="pmid">3821906</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Global Lipids Genetics Consortium</collab><name><surname>Willer</surname> <given-names>CJ</given-names></name><name><surname>Schmidt</surname> <given-names>EM</given-names></name><name><surname>Sengupta</surname> <given-names>S</given-names></name><name><surname>Peloso</surname> <given-names>GM</given-names></name><name><surname>Gustafsson</surname> <given-names>S</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Ganna</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Buchkovich</surname> <given-names>ML</given-names></name><name><surname>Mora</surname> <given-names>S</given-names></name><name><surname>Beckmann</surname> <given-names>JS</given-names></name><name><surname>Bragg-Gresham</surname> <given-names>JL</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Demirkan</surname> <given-names>A</given-names></name><name><surname>Den Hertog</surname> <given-names>HM</given-names></name><name><surname>Do</surname> <given-names>R</given-names></name><name><surname>Donnelly</surname> <given-names>LA</given-names></name><name><surname>Ehret</surname> <given-names>GB</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Feitosa</surname> <given-names>MF</given-names></name><name><surname>Ferreira</surname> <given-names>T</given-names></name><name><surname>Fischer</surname> <given-names>K</given-names></name><name><surname>Fontanillas</surname> <given-names>P</given-names></name><name><surname>Fraser</surname> <given-names>RM</given-names></name><name><surname>Freitag</surname> <given-names>DF</given-names></name><name><surname>Gurdasani</surname> <given-names>D</given-names></name><name><surname>Heikkilä</surname> <given-names>K</given-names></name><name><surname>Hyppönen</surname> <given-names>E</given-names></name><name><surname>Isaacs</surname> <given-names>A</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Johansson</surname> <given-names>Å</given-names></name><name><surname>Johnson</surname> <given-names>T</given-names></name><name><surname>Kaakinen</surname> <given-names>M</given-names></name><name><surname>Kettunen</surname> <given-names>J</given-names></name><name><surname>Kleber</surname> <given-names>ME</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Lyytikäinen</surname> <given-names>LP</given-names></name><name><surname>Magnusson</surname> <given-names>PKE</given-names></name><name><surname>Mangino</surname> <given-names>M</given-names></name><name><surname>Mihailov</surname> <given-names>E</given-names></name><name><surname>Montasser</surname> <given-names>ME</given-names></name><name><surname>Müller-Nurasyid</surname> <given-names>M</given-names></name><name><surname>Nolte</surname> <given-names>IM</given-names></name><name><surname>O'Connell</surname> <given-names>JR</given-names></name><name><surname>Palmer</surname> <given-names>CD</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Petersen</surname> <given-names>AK</given-names></name><name><surname>Sanna</surname> <given-names>S</given-names></name><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Service</surname> <given-names>SK</given-names></name><name><surname>Shah</surname> <given-names>S</given-names></name><name><surname>Shungin</surname> <given-names>D</given-names></name><name><surname>Sidore</surname> <given-names>C</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Strawbridge</surname> <given-names>RJ</given-names></name><name><surname>Surakka</surname> <given-names>I</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Teslovich</surname> <given-names>TM</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Van den Herik</surname> <given-names>EG</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Volcik</surname> <given-names>KA</given-names></name><name><surname>Waite</surname> <given-names>LL</given-names></name><name><surname>Wong</surname> <given-names>A</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Absher</surname> <given-names>D</given-names></name><name><surname>Asiki</surname> <given-names>G</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Been</surname> <given-names>LF</given-names></name><name><surname>Bolton</surname> <given-names>JL</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Brambilla</surname> <given-names>P</given-names></name><name><surname>Burnett</surname> <given-names>MS</given-names></name><name><surname>Cesana</surname> <given-names>G</given-names></name><name><surname>Dimitriou</surname> <given-names>M</given-names></name><name><surname>Doney</surname> <given-names>ASF</given-names></name><name><surname>Döring</surname> <given-names>A</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Epstein</surname> <given-names>SE</given-names></name><name><surname>Ingi Eyjolfsson</surname> <given-names>G</given-names></name><name><surname>Gigante</surname> <given-names>B</given-names></name><name><surname>Goodarzi</surname> <given-names>MO</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Gravito</surname> <given-names>ML</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Hallmans</surname> <given-names>G</given-names></name><name><surname>Hartikainen</surname> <given-names>AL</given-names></name><name><surname>Hayward</surname> <given-names>C</given-names></name><name><surname>Hernandez</surname> <given-names>D</given-names></name><name><surname>Hicks</surname> <given-names>AA</given-names></name><name><surname>Holm</surname> <given-names>H</given-names></name><name><surname>Hung</surname> <given-names>YJ</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Jones</surname> <given-names>MR</given-names></name><name><surname>Kaleebu</surname> <given-names>P</given-names></name><name><surname>Kastelein</surname> <given-names>JJP</given-names></name><name><surname>Khaw</surname> <given-names>KT</given-names></name><name><surname>Kim</surname> <given-names>E</given-names></name><name><surname>Klopp</surname> <given-names>N</given-names></name><name><surname>Komulainen</surname> <given-names>P</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Lin</surname> <given-names>SY</given-names></name><name><surname>Lindström</surname> <given-names>J</given-names></name><name><surname>Loos</surname> <given-names>RJF</given-names></name><name><surname>Mach</surname> <given-names>F</given-names></name><name><surname>McArdle</surname> <given-names>WL</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Mitchell</surname> <given-names>BD</given-names></name><name><surname>Müller</surname> <given-names>G</given-names></name><name><surname>Nagaraja</surname> <given-names>R</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Nieminen</surname> <given-names>TVM</given-names></name><name><surname>Nsubuga</surname> <given-names>RN</given-names></name><name><surname>Olafsson</surname> <given-names>I</given-names></name><name><surname>Ong</surname> <given-names>KK</given-names></name><name><surname>Palotie</surname> <given-names>A</given-names></name><name><surname>Papamarkou</surname> <given-names>T</given-names></name><name><surname>Pomilla</surname> <given-names>C</given-names></name><name><surname>Pouta</surname> <given-names>A</given-names></name><name><surname>Rader</surname> <given-names>DJ</given-names></name><name><surname>Reilly</surname> <given-names>MP</given-names></name><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Rivadeneira</surname> <given-names>F</given-names></name><name><surname>Rudan</surname> <given-names>I</given-names></name><name><surname>Ruokonen</surname> <given-names>A</given-names></name><name><surname>Samani</surname> <given-names>N</given-names></name><name><surname>Scharnagl</surname> <given-names>H</given-names></name><name><surname>Seeley</surname> <given-names>J</given-names></name><name><surname>Silander</surname> <given-names>K</given-names></name><name><surname>Stančáková</surname> <given-names>A</given-names></name><name><surname>Stirrups</surname> <given-names>K</given-names></name><name><surname>Swift</surname> <given-names>AJ</given-names></name><name><surname>Tiret</surname> <given-names>L</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>van Pelt</surname> <given-names>LJ</given-names></name><name><surname>Vedantam</surname> <given-names>S</given-names></name><name><surname>Wainwright</surname> <given-names>N</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Wild</surname> <given-names>SH</given-names></name><name><surname>Willemsen</surname> <given-names>G</given-names></name><name><surname>Wilsgaard</surname> <given-names>T</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Young</surname> <given-names>EH</given-names></name><name><surname>Zhao</surname> <given-names>JH</given-names></name><name><surname>Adair</surname> <given-names>LS</given-names></name><name><surname>Arveiler</surname> <given-names>D</given-names></name><name><surname>Assimes</surname> <given-names>TL</given-names></name><name><surname>Bandinelli</surname> <given-names>S</given-names></name><name><surname>Bennett</surname> <given-names>F</given-names></name><name><surname>Bochud</surname> <given-names>M</given-names></name><name><surname>Boehm</surname> <given-names>BO</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Borecki</surname> <given-names>IB</given-names></name><name><surname>Bornstein</surname> <given-names>SR</given-names></name><name><surname>Bovet</surname> <given-names>P</given-names></name><name><surname>Burnier</surname> <given-names>M</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Chakravarti</surname> <given-names>A</given-names></name><name><surname>Chambers</surname> <given-names>JC</given-names></name><name><surname>Chen</surname> <given-names>YI</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Cooper</surname> <given-names>RS</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Dedoussis</surname> <given-names>G</given-names></name><name><surname>de Faire</surname> <given-names>U</given-names></name><name><surname>Feranil</surname> <given-names>AB</given-names></name><name><surname>Ferrières</surname> <given-names>J</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Freimer</surname> <given-names>NB</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Groop</surname> <given-names>LC</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Gyllensten</surname> <given-names>U</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Harris</surname> <given-names>TB</given-names></name><name><surname>Hingorani</surname> <given-names>A</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Hovingh</surname> <given-names>GK</given-names></name><name><surname>Hsiung</surname> <given-names>CA</given-names></name><name><surname>Humphries</surname> <given-names>SE</given-names></name><name><surname>Hunt</surname> <given-names>SC</given-names></name><name><surname>Hveem</surname> <given-names>K</given-names></name><name><surname>Iribarren</surname> <given-names>C</given-names></name><name><surname>Järvelin</surname> <given-names>MR</given-names></name><name><surname>Jula</surname> <given-names>A</given-names></name><name><surname>Kähönen</surname> <given-names>M</given-names></name><name><surname>Kaprio</surname> <given-names>J</given-names></name><name><surname>Kesäniemi</surname> <given-names>A</given-names></name><name><surname>Kivimaki</surname> <given-names>M</given-names></name><name><surname>Kooner</surname> <given-names>JS</given-names></name><name><surname>Koudstaal</surname> <given-names>PJ</given-names></name><name><surname>Krauss</surname> <given-names>RM</given-names></name><name><surname>Kuh</surname> <given-names>D</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Kyvik</surname> <given-names>KO</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Lakka</surname> <given-names>TA</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>März</surname> <given-names>W</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>McKenzie</surname> <given-names>CA</given-names></name><name><surname>Meneton</surname> <given-names>P</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Moilanen</surname> <given-names>L</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Munroe</surname> <given-names>PB</given-names></name><name><surname>Njølstad</surname> <given-names>I</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Power</surname> <given-names>C</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Price</surname> <given-names>JF</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Quertermous</surname> <given-names>T</given-names></name><name><surname>Rauramaa</surname> <given-names>R</given-names></name><name><surname>Saleheen</surname> <given-names>D</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Sanghera</surname> <given-names>DK</given-names></name><name><surname>Saramies</surname> <given-names>J</given-names></name><name><surname>Schwarz</surname> <given-names>PEH</given-names></name><name><surname>Sheu</surname> <given-names>WH</given-names></name><name><surname>Shuldiner</surname> <given-names>AR</given-names></name><name><surname>Siegbahn</surname> <given-names>A</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Strachan</surname> <given-names>DP</given-names></name><name><surname>Tayo</surname> <given-names>BO</given-names></name><name><surname>Tremoli</surname> <given-names>E</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Uusitupa</surname> <given-names>M</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Vollenweider</surname> <given-names>P</given-names></name><name><surname>Wallentin</surname> <given-names>L</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Whitfield</surname> <given-names>JB</given-names></name><name><surname>Wolffenbuttel</surname> <given-names>BHR</given-names></name><name><surname>Ordovas</surname> <given-names>JM</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Palmer</surname> <given-names>CNA</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Chasman</surname> <given-names>DI</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Franks</surname> <given-names>PW</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Cupples</surname> <given-names>LA</given-names></name><name><surname>Sandhu</surname> <given-names>MS</given-names></name><name><surname>Rich</surname> <given-names>SS</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Discovery and refinement of loci associated with lipid levels</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1274</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1038/ng.2797</pub-id><pub-id pub-id-type="pmid">24097068</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goardon</surname> <given-names>N</given-names></name><name><surname>Lambert</surname> <given-names>JA</given-names></name><name><surname>Rodriguez</surname> <given-names>P</given-names></name><name><surname>Nissaire</surname> <given-names>P</given-names></name><name><surname>Herblot</surname> <given-names>S</given-names></name><name><surname>Thibault</surname> <given-names>P</given-names></name><name><surname>Dumenil</surname> <given-names>D</given-names></name><name><surname>Strouboulis</surname> <given-names>J</given-names></name><name><surname>Romeo</surname> <given-names>PH</given-names></name><name><surname>Hoang</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>ETO2 coordinates cellular proliferation and differentiation during erythropoiesis</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600934</pub-id><pub-id pub-id-type="pmid">16407974</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gozani</surname> <given-names>O</given-names></name><name><surname>Feld</surname> <given-names>R</given-names></name><name><surname>Reed</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Evidence that sequence-independent binding of highly conserved U2 snRNP proteins upstream of the branch site is required for assembly of spliceosomal complex A</article-title><source>Genes &amp; Development</source><volume>10</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1101/gad.10.2.233</pub-id><pub-id pub-id-type="pmid">8566756</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gozani</surname> <given-names>O</given-names></name><name><surname>Potashkin</surname> <given-names>J</given-names></name><name><surname>Reed</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>4752</fpage><lpage>4760</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.8.4752</pub-id><pub-id pub-id-type="pmid">9671485</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Human genomics. the Genotype-Tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans</article-title><source>Science</source><volume>348</volume><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1126/science.1262110</pub-id><pub-id pub-id-type="pmid">25954001</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>MH</given-names></name><name><surname>Nandakumar</surname> <given-names>SK</given-names></name><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Zekavat</surname> <given-names>SM</given-names></name><name><surname>Buenrostro</surname> <given-names>JD</given-names></name><name><surname>Natarajan</surname> <given-names>P</given-names></name><name><surname>Salem</surname> <given-names>RM</given-names></name><name><surname>Chiarle</surname> <given-names>R</given-names></name><name><surname>Mitt</surname> <given-names>M</given-names></name><name><surname>Kals</surname> <given-names>M</given-names></name><name><surname>Pärn</surname> <given-names>K</given-names></name><name><surname>Fischer</surname> <given-names>K</given-names></name><name><surname>Milani</surname> <given-names>L</given-names></name><name><surname>Mägi</surname> <given-names>R</given-names></name><name><surname>Palta</surname> <given-names>P</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms</article-title><source>Proceedings of the National Academy of Sciences</source><volume>114</volume><fpage>E327</fpage><lpage>E336</lpage><pub-id pub-id-type="doi">10.1073/pnas.1619052114</pub-id><pub-id pub-id-type="pmid">28031487</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>RM</given-names></name><name><surname>Hadaya</surname> <given-names>J</given-names></name><name><surname>Trehan</surname> <given-names>A</given-names></name><name><surname>Zekavat</surname> <given-names>SM</given-names></name><name><surname>Roselli</surname> <given-names>C</given-names></name><name><surname>Klarin</surname> <given-names>D</given-names></name><name><surname>Emdin</surname> <given-names>CA</given-names></name><name><surname>Hilvering</surname> <given-names>CRE</given-names></name><name><surname>Bianchi</surname> <given-names>V</given-names></name><name><surname>Mueller</surname> <given-names>C</given-names></name><name><surname>Khera</surname> <given-names>AV</given-names></name><name><surname>Ryan</surname> <given-names>RJH</given-names></name><name><surname>Engreitz</surname> <given-names>JM</given-names></name><name><surname>Issner</surname> <given-names>R</given-names></name><name><surname>Shoresh</surname> <given-names>N</given-names></name><name><surname>Epstein</surname> <given-names>CB</given-names></name><name><surname>de Laat</surname> <given-names>W</given-names></name><name><surname>Brown</surname> <given-names>JD</given-names></name><name><surname>Schnabel</surname> <given-names>RB</given-names></name><name><surname>Bernstein</surname> <given-names>BE</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A genetic variant associated with five vascular diseases is a distal regulator of Endothelin-1 gene expression</article-title><source>Cell</source><volume>170</volume><fpage>522</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.049</pub-id><pub-id pub-id-type="pmid">28753427</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Xue</surname> <given-names>F</given-names></name><name><surname>Halverson</surname> <given-names>G</given-names></name><name><surname>Reid</surname> <given-names>M</given-names></name><name><surname>Guo</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Raza</surname> <given-names>A</given-names></name><name><surname>Galili</surname> <given-names>N</given-names></name><name><surname>Jaffray</surname> <given-names>J</given-names></name><name><surname>Lane</surname> <given-names>J</given-names></name><name><surname>Chasis</surname> <given-names>JA</given-names></name><name><surname>Taylor</surname> <given-names>N</given-names></name><name><surname>Mohandas</surname> <given-names>N</given-names></name><name><surname>An</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo</article-title><source>Blood</source><volume>121</volume><fpage>3246</fpage><lpage>3253</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-01-476390</pub-id><pub-id pub-id-type="pmid">23422750</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Inflammatory Bowel Disease Genetics Consortium</collab><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Fang</surname> <given-names>M</given-names></name><name><surname>Jostins</surname> <given-names>L</given-names></name><name><surname>Umićević Mirkov</surname> <given-names>M</given-names></name><name><surname>Boucher</surname> <given-names>G</given-names></name><name><surname>Anderson</surname> <given-names>CA</given-names></name><name><surname>Andersen</surname> <given-names>V</given-names></name><name><surname>Cleynen</surname> <given-names>I</given-names></name><name><surname>Cortes</surname> <given-names>A</given-names></name><name><surname>Crins</surname> <given-names>F</given-names></name><name><surname>D'Amato</surname> <given-names>M</given-names></name><name><surname>Deffontaine</surname> <given-names>V</given-names></name><name><surname>Dmitrieva</surname> <given-names>J</given-names></name><name><surname>Docampo</surname> <given-names>E</given-names></name><name><surname>Elansary</surname> <given-names>M</given-names></name><name><surname>Farh</surname> <given-names>KK</given-names></name><name><surname>Franke</surname> <given-names>A</given-names></name><name><surname>Gori</surname> <given-names>AS</given-names></name><name><surname>Goyette</surname> <given-names>P</given-names></name><name><surname>Halfvarson</surname> <given-names>J</given-names></name><name><surname>Haritunians</surname> <given-names>T</given-names></name><name><surname>Knight</surname> <given-names>J</given-names></name><name><surname>Lawrance</surname> <given-names>IC</given-names></name><name><surname>Lees</surname> <given-names>CW</given-names></name><name><surname>Louis</surname> <given-names>E</given-names></name><name><surname>Mariman</surname> <given-names>R</given-names></name><name><surname>Meuwissen</surname> <given-names>T</given-names></name><name><surname>Mni</surname> <given-names>M</given-names></name><name><surname>Momozawa</surname> <given-names>Y</given-names></name><name><surname>Parkes</surname> <given-names>M</given-names></name><name><surname>Spain</surname> <given-names>SL</given-names></name><name><surname>Théâtre</surname> <given-names>E</given-names></name><name><surname>Trynka</surname> <given-names>G</given-names></name><name><surname>Satsangi</surname> <given-names>J</given-names></name><name><surname>van Sommeren</surname> <given-names>S</given-names></name><name><surname>Vermeire</surname> <given-names>S</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Weersma</surname> <given-names>RK</given-names></name><name><surname>Duerr</surname> <given-names>RH</given-names></name><name><surname>Mathew</surname> <given-names>CG</given-names></name><name><surname>Rioux</surname> <given-names>JD</given-names></name><name><surname>McGovern</surname> <given-names>DPB</given-names></name><name><surname>Cho</surname> <given-names>JH</given-names></name><name><surname>Georges</surname> <given-names>M</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Barrett</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fine-mapping inflammatory bowel disease loci to single-variant resolution</article-title><source>Nature</source><volume>547</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1038/nature22969</pub-id><pub-id pub-id-type="pmid">28658209</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Inflammatory Bowel Disease Genetics Constortium</collab><name><surname>Rossin</surname> <given-names>EJ</given-names></name><name><surname>Lage</surname> <given-names>K</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Tatar</surname> <given-names>D</given-names></name><name><surname>Benita</surname> <given-names>Y</given-names></name><name><surname>Cotsapas</surname> <given-names>C</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology</article-title><source>PLOS Genetics</source><volume>7</volume><elocation-id>e1001273</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1001273</pub-id><pub-id pub-id-type="pmid">21249183</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname> <given-names>H</given-names></name><name><surname>Vakoc</surname> <given-names>CR</given-names></name><name><surname>Ying</surname> <given-names>L</given-names></name><name><surname>Mandat</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Blobel</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Exchange of GATA factors mediates transitions in looped chromatin organization at a developmentally regulated gene locus</article-title><source>Molecular Cell</source><volume>29</volume><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.11.020</pub-id><pub-id pub-id-type="pmid">18243117</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>ET</given-names></name><name><surname>Airoldi</surname> <given-names>EM</given-names></name><name><surname>Burge</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Analysis and design of RNA sequencing experiments for identifying isoform regulation</article-title><source>Nature Methods</source><volume>7</volume><fpage>1009</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1528</pub-id><pub-id pub-id-type="pmid">21057496</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khajuria</surname> <given-names>RK</given-names></name><name><surname>Munschauer</surname> <given-names>M</given-names></name><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Fiorini</surname> <given-names>C</given-names></name><name><surname>Ludwig</surname> <given-names>LS</given-names></name><name><surname>McFarland</surname> <given-names>SK</given-names></name><name><surname>Abdulhay</surname> <given-names>NJ</given-names></name><name><surname>Specht</surname> <given-names>H</given-names></name><name><surname>Keshishian</surname> <given-names>H</given-names></name><name><surname>Mani</surname> <given-names>DR</given-names></name><name><surname>Jovanovic</surname> <given-names>M</given-names></name><name><surname>Ellis</surname> <given-names>SR</given-names></name><name><surname>Fulco</surname> <given-names>CP</given-names></name><name><surname>Engreitz</surname> <given-names>JM</given-names></name><name><surname>Schütz</surname> <given-names>S</given-names></name><name><surname>Lian</surname> <given-names>J</given-names></name><name><surname>Gripp</surname> <given-names>KW</given-names></name><name><surname>Weinberg</surname> <given-names>OK</given-names></name><name><surname>Pinkus</surname> <given-names>GS</given-names></name><name><surname>Gehrke</surname> <given-names>L</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Gazda</surname> <given-names>HT</given-names></name><name><surname>Lee</surname> <given-names>WY</given-names></name><name><surname>Panse</surname> <given-names>VG</given-names></name><name><surname>Carr</surname> <given-names>SA</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ribosome levels selectively regulate translation and lineage commitment in human hematopoiesis</article-title><source>Cell</source><volume>173</volume><fpage>90</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.02.036</pub-id><pub-id pub-id-type="pmid">29551269</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>AR</given-names></name><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Unal</surname> <given-names>E</given-names></name><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Karakukcu</surname> <given-names>M</given-names></name><name><surname>Yuan</surname> <given-names>D</given-names></name><name><surname>Kazerounian</surname> <given-names>S</given-names></name><name><surname>Abdulhay</surname> <given-names>NJ</given-names></name><name><surname>King</surname> <given-names>DS</given-names></name><name><surname>Gupta</surname> <given-names>N</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Patiroglu</surname> <given-names>T</given-names></name><name><surname>Ozcan</surname> <given-names>A</given-names></name><name><surname>Ozdemir</surname> <given-names>MA</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name><name><surname>Gazda</surname> <given-names>HT</given-names></name><name><surname>Klein</surname> <given-names>DE</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Functional selectivity in cytokine signaling revealed through a pathogenic EPO mutation</article-title><source>Cell</source><volume>168</volume><fpage>1053</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.02.026</pub-id><pub-id pub-id-type="pmid">28283061</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Köster</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Xiao</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>JS</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR</article-title><source>Genome Biology</source><volume>16</volume><elocation-id>281</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-015-0843-6</pub-id><pub-id pub-id-type="pmid">26673418</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>N</given-names></name><name><surname>Hargreaves</surname> <given-names>VV</given-names></name><name><surname>Zhu</surname> <given-names>Q</given-names></name><name><surname>Kurland</surname> <given-names>JV</given-names></name><name><surname>Hong</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>W</given-names></name><name><surname>Sher</surname> <given-names>F</given-names></name><name><surname>Macias-Trevino</surname> <given-names>C</given-names></name><name><surname>Rogers</surname> <given-names>JM</given-names></name><name><surname>Kurita</surname> <given-names>R</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Yuan</surname> <given-names>GC</given-names></name><name><surname>Bauer</surname> <given-names>DE</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Bulyk</surname> <given-names>ML</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch</article-title><source>Cell</source><volume>173</volume><fpage>430</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.016</pub-id><pub-id pub-id-type="pmid">29606353</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname> <given-names>LS</given-names></name><name><surname>Gazda</surname> <given-names>HT</given-names></name><name><surname>Eng</surname> <given-names>JC</given-names></name><name><surname>Eichhorn</surname> <given-names>SW</given-names></name><name><surname>Thiru</surname> <given-names>P</given-names></name><name><surname>Ghazvinian</surname> <given-names>R</given-names></name><name><surname>George</surname> <given-names>TI</given-names></name><name><surname>Gotlib</surname> <given-names>JR</given-names></name><name><surname>Beggs</surname> <given-names>AH</given-names></name><name><surname>Sieff</surname> <given-names>CA</given-names></name><name><surname>Lodish</surname> <given-names>HF</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Altered translation of GATA1 in Diamond-Blackfan anemia</article-title><source>Nature Medicine</source><volume>20</volume><fpage>748</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1038/nm.3557</pub-id><pub-id pub-id-type="pmid">24952648</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandegar</surname> <given-names>MA</given-names></name><name><surname>Huebsch</surname> <given-names>N</given-names></name><name><surname>Frolov</surname> <given-names>EB</given-names></name><name><surname>Shin</surname> <given-names>E</given-names></name><name><surname>Truong</surname> <given-names>A</given-names></name><name><surname>Olvera</surname> <given-names>MP</given-names></name><name><surname>Chan</surname> <given-names>AH</given-names></name><name><surname>Miyaoka</surname> <given-names>Y</given-names></name><name><surname>Holmes</surname> <given-names>K</given-names></name><name><surname>Spencer</surname> <given-names>CI</given-names></name><name><surname>Judge</surname> <given-names>LM</given-names></name><name><surname>Gordon</surname> <given-names>DE</given-names></name><name><surname>Eskildsen</surname> <given-names>TV</given-names></name><name><surname>Villalta</surname> <given-names>JE</given-names></name><name><surname>Horlbeck</surname> <given-names>MA</given-names></name><name><surname>Gilbert</surname> <given-names>LA</given-names></name><name><surname>Krogan</surname> <given-names>NJ</given-names></name><name><surname>Sheikh</surname> <given-names>SP</given-names></name><name><surname>Weissman</surname> <given-names>JS</given-names></name><name><surname>Qi</surname> <given-names>LS</given-names></name><name><surname>So</surname> <given-names>PL</given-names></name><name><surname>Conklin</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs</article-title><source>Cell Stem Cell</source><volume>18</volume><fpage>541</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.01.022</pub-id><pub-id pub-id-type="pmid">26971820</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIver</surname> <given-names>SC</given-names></name><name><surname>Kang</surname> <given-names>YA</given-names></name><name><surname>DeVilbiss</surname> <given-names>AW</given-names></name><name><surname>O'Driscoll</surname> <given-names>CA</given-names></name><name><surname>Ouellette</surname> <given-names>JN</given-names></name><name><surname>Pope</surname> <given-names>NJ</given-names></name><name><surname>Camprecios</surname> <given-names>G</given-names></name><name><surname>Chang</surname> <given-names>CJ</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Bouhassira</surname> <given-names>EE</given-names></name><name><surname>Ghaffari</surname> <given-names>S</given-names></name><name><surname>Bresnick</surname> <given-names>EH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The exosome complex establishes a barricade to erythroid maturation</article-title><source>Blood</source><volume>124</volume><fpage>2285</fpage><lpage>2297</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-04-571083</pub-id><pub-id pub-id-type="pmid">25115889</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaren</surname> <given-names>W</given-names></name><name><surname>Gil</surname> <given-names>L</given-names></name><name><surname>Hunt</surname> <given-names>SE</given-names></name><name><surname>Riat</surname> <given-names>HS</given-names></name><name><surname>Ritchie</surname> <given-names>GR</given-names></name><name><surname>Thormann</surname> <given-names>A</given-names></name><name><surname>Flicek</surname> <given-names>P</given-names></name><name><surname>Cunningham</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The ensembl variant effect predictor</article-title><source>Genome Biology</source><volume>17</volume><pub-id pub-id-type="doi">10.1186/s13059-016-0974-4</pub-id><pub-id pub-id-type="pmid">27268795</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffat</surname> <given-names>J</given-names></name><name><surname>Grueneberg</surname> <given-names>DA</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Kim</surname> <given-names>SY</given-names></name><name><surname>Kloepfer</surname> <given-names>AM</given-names></name><name><surname>Hinkle</surname> <given-names>G</given-names></name><name><surname>Piqani</surname> <given-names>B</given-names></name><name><surname>Eisenhaure</surname> <given-names>TM</given-names></name><name><surname>Luo</surname> <given-names>B</given-names></name><name><surname>Grenier</surname> <given-names>JK</given-names></name><name><surname>Carpenter</surname> <given-names>AE</given-names></name><name><surname>Foo</surname> <given-names>SY</given-names></name><name><surname>Stewart</surname> <given-names>SA</given-names></name><name><surname>Stockwell</surname> <given-names>BR</given-names></name><name><surname>Hacohen</surname> <given-names>N</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen</article-title><source>Cell</source><volume>124</volume><fpage>1283</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.01.040</pub-id><pub-id pub-id-type="pmid">16564017</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohanan</surname> <given-names>V</given-names></name><name><surname>Nakata</surname> <given-names>T</given-names></name><name><surname>Desch</surname> <given-names>AN</given-names></name><name><surname>Lévesque</surname> <given-names>C</given-names></name><name><surname>Boroughs</surname> <given-names>A</given-names></name><name><surname>Guzman</surname> <given-names>G</given-names></name><name><surname>Cao</surname> <given-names>Z</given-names></name><name><surname>Creasey</surname> <given-names>E</given-names></name><name><surname>Yao</surname> <given-names>J</given-names></name><name><surname>Boucher</surname> <given-names>G</given-names></name><name><surname>Charron</surname> <given-names>G</given-names></name><name><surname>Bhan</surname> <given-names>AK</given-names></name><name><surname>Schenone</surname> <given-names>M</given-names></name><name><surname>Carr</surname> <given-names>SA</given-names></name><name><surname>Reinecker</surname> <given-names>HC</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Rioux</surname> <given-names>JD</given-names></name><name><surname>Lassen</surname> <given-names>KG</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>C1orf106</italic> is a colitis risk gene that regulates stability of epithelial adherens junctions</article-title><source>Science</source><volume>359</volume><fpage>1161</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1126/science.aan0814</pub-id><pub-id pub-id-type="pmid">29420262</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname> <given-names>SB</given-names></name><name><surname>Dermitzakis</surname> <given-names>ET</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>From expression QTLs to personalized transcriptomics</article-title><source>Nature Reviews Genetics</source><volume>12</volume><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1038/nrg2969</pub-id><pub-id pub-id-type="pmid">21386863</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucenski</surname> <given-names>ML</given-names></name><name><surname>McLain</surname> <given-names>K</given-names></name><name><surname>Kier</surname> <given-names>AB</given-names></name><name><surname>Swerdlow</surname> <given-names>SH</given-names></name><name><surname>Schreiner</surname> <given-names>CM</given-names></name><name><surname>Miller</surname> <given-names>TA</given-names></name><name><surname>Pietryga</surname> <given-names>DW</given-names></name><name><surname>Scott</surname> <given-names>WJ</given-names></name><name><surname>Potter</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis</article-title><source>Cell</source><volume>65</volume><fpage>677</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90099-K</pub-id><pub-id pub-id-type="pmid">1709592</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musunuru</surname> <given-names>K</given-names></name><name><surname>Strong</surname> <given-names>A</given-names></name><name><surname>Frank-Kamenetsky</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>NE</given-names></name><name><surname>Ahfeldt</surname> <given-names>T</given-names></name><name><surname>Sachs</surname> <given-names>KV</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Kuperwasser</surname> <given-names>N</given-names></name><name><surname>Ruda</surname> <given-names>VM</given-names></name><name><surname>Pirruccello</surname> <given-names>JP</given-names></name><name><surname>Muchmore</surname> <given-names>B</given-names></name><name><surname>Prokunina-Olsson</surname> <given-names>L</given-names></name><name><surname>Hall</surname> <given-names>JL</given-names></name><name><surname>Schadt</surname> <given-names>EE</given-names></name><name><surname>Morales</surname> <given-names>CR</given-names></name><name><surname>Lund-Katz</surname> <given-names>S</given-names></name><name><surname>Phillips</surname> <given-names>MC</given-names></name><name><surname>Wong</surname> <given-names>J</given-names></name><name><surname>Cantley</surname> <given-names>W</given-names></name><name><surname>Racie</surname> <given-names>T</given-names></name><name><surname>Ejebe</surname> <given-names>KG</given-names></name><name><surname>Orho-Melander</surname> <given-names>M</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Koteliansky</surname> <given-names>V</given-names></name><name><surname>Fitzgerald</surname> <given-names>K</given-names></name><name><surname>Krauss</surname> <given-names>RM</given-names></name><name><surname>Cowan</surname> <given-names>CA</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>Rader</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus</article-title><source>Nature</source><volume>466</volume><fpage>714</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1038/nature09266</pub-id><pub-id pub-id-type="pmid">20686566</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nai</surname> <given-names>A</given-names></name><name><surname>Lidonnici</surname> <given-names>MR</given-names></name><name><surname>Rausa</surname> <given-names>M</given-names></name><name><surname>Mandelli</surname> <given-names>G</given-names></name><name><surname>Pagani</surname> <given-names>A</given-names></name><name><surname>Silvestri</surname> <given-names>L</given-names></name><name><surname>Ferrari</surname> <given-names>G</given-names></name><name><surname>Camaschella</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The second transferrin receptor regulates red blood cell production in mice</article-title><source>Blood</source><volume>125</volume><fpage>1170</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-08-596254</pub-id><pub-id pub-id-type="pmid">25499454</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Nandakumar</surname> <given-names>SK</given-names></name><name><surname>McFarland</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>shRNA_screen</data-title><source>GitHub</source><version designator="920f190">920f190</version><ext-link ext-link-type="uri" xlink:href="https://github.com/sankaranlab/shRNA_screen">https://github.com/sankaranlab/shRNA_screen</ext-link></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemi</surname> <given-names>MEK</given-names></name><name><surname>Martin</surname> <given-names>HC</given-names></name><name><surname>Rice</surname> <given-names>DL</given-names></name><name><surname>Gallone</surname> <given-names>G</given-names></name><name><surname>Gordon</surname> <given-names>S</given-names></name><name><surname>Kelemen</surname> <given-names>M</given-names></name><name><surname>McAloney</surname> <given-names>K</given-names></name><name><surname>McRae</surname> <given-names>J</given-names></name><name><surname>Radford</surname> <given-names>EJ</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Gecz</surname> <given-names>J</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>Wright</surname> <given-names>CF</given-names></name><name><surname>Fitzpatrick</surname> <given-names>DR</given-names></name><name><surname>Firth</surname> <given-names>HV</given-names></name><name><surname>Hurles</surname> <given-names>ME</given-names></name><name><surname>Barrett</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Common genetic variants contribute to risk of rare severe neurodevelopmental disorders</article-title><source>Nature</source><volume>562</volume><fpage>268</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0566-4</pub-id><pub-id pub-id-type="pmid">30258228</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obeng</surname> <given-names>EA</given-names></name><name><surname>Chappell</surname> <given-names>RJ</given-names></name><name><surname>Seiler</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>MC</given-names></name><name><surname>Campagna</surname> <given-names>DR</given-names></name><name><surname>Schmidt</surname> <given-names>PJ</given-names></name><name><surname>Schneider</surname> <given-names>RK</given-names></name><name><surname>Lord</surname> <given-names>AM</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Gambe</surname> <given-names>RG</given-names></name><name><surname>McConkey</surname> <given-names>ME</given-names></name><name><surname>Ali</surname> <given-names>AM</given-names></name><name><surname>Raza</surname> <given-names>A</given-names></name><name><surname>Yu</surname> <given-names>L</given-names></name><name><surname>Buonamici</surname> <given-names>S</given-names></name><name><surname>Smith</surname> <given-names>PG</given-names></name><name><surname>Mullally</surname> <given-names>A</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Fleming</surname> <given-names>MD</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Physiologic expression of Sf3b1(K700E) Causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation</article-title><source>Cancer Cell</source><volume>30</volume><fpage>404</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.08.006</pub-id><pub-id pub-id-type="pmid">27622333</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname> <given-names>R</given-names></name><name><surname>Duggal</surname> <given-names>G</given-names></name><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Irizarry</surname> <given-names>RA</given-names></name><name><surname>Kingsford</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nature Methods</source><volume>14</volume><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname> <given-names>LL</given-names></name><name><surname>Shivdasani</surname> <given-names>RA</given-names></name><name><surname>Liu</surname> <given-names>SC</given-names></name><name><surname>Hanspal</surname> <given-names>M</given-names></name><name><surname>John</surname> <given-names>KM</given-names></name><name><surname>Gonzalez</surname> <given-names>JM</given-names></name><name><surname>Brugnara</surname> <given-names>C</given-names></name><name><surname>Gwynn</surname> <given-names>B</given-names></name><name><surname>Mohandas</surname> <given-names>N</given-names></name><name><surname>Alper</surname> <given-names>SL</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Lux</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton</article-title><source>Cell</source><volume>86</volume><fpage>917</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80167-1</pub-id><pub-id pub-id-type="pmid">8808627</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picelli</surname> <given-names>S</given-names></name><name><surname>Faridani</surname> <given-names>OR</given-names></name><name><surname>Björklund</surname> <given-names>AK</given-names></name><name><surname>Winberg</surname> <given-names>G</given-names></name><name><surname>Sagasser</surname> <given-names>S</given-names></name><name><surname>Sandberg</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Full-length RNA-seq from single cells using Smart-seq2</article-title><source>Nature Protocols</source><volume>9</volume><fpage>171</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1038/nprot.2014.006</pub-id><pub-id pub-id-type="pmid">24385147</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Parra</surname> <given-names>M</given-names></name><name><surname>Gee</surname> <given-names>SL</given-names></name><name><surname>Mohandas</surname> <given-names>N</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name><name><surname>Conboy</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A dynamic intron retention program enriched in RNA processing genes regulates gene expression during terminal erythropoiesis</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>838</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1168</pub-id><pub-id pub-id-type="pmid">26531823</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riba</surname> <given-names>A</given-names></name><name><surname>Emmenlauer</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>A</given-names></name><name><surname>Sigoillot</surname> <given-names>F</given-names></name><name><surname>Cong</surname> <given-names>F</given-names></name><name><surname>Dehio</surname> <given-names>C</given-names></name><name><surname>Jenkins</surname> <given-names>J</given-names></name><name><surname>Zavolan</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Explicit modeling of siRNA-Dependent on- and Off-Target repression improves the interpretation of screening results</article-title><source>Cell Systems</source><volume>4</volume><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2017.01.011</pub-id><pub-id pub-id-type="pmid">28215525</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname> <given-names>A</given-names></name><name><surname>Kontarakis</surname> <given-names>Z</given-names></name><name><surname>Gerri</surname> <given-names>C</given-names></name><name><surname>Nolte</surname> <given-names>H</given-names></name><name><surname>Hölper</surname> <given-names>S</given-names></name><name><surname>Krüger</surname> <given-names>M</given-names></name><name><surname>Stainier</surname> <given-names>DY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic compensation induced by deleterious mutations but not gene knockdowns</article-title><source>Nature</source><volume>524</volume><fpage>230</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/nature14580</pub-id><pub-id pub-id-type="pmid">26168398</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rund</surname> <given-names>D</given-names></name><name><surname>Rachmilewitz</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Beta-thalassemia</article-title><source>The New England Journal of Medicine</source><volume>353</volume><fpage>1135</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1056/NEJMra050436</pub-id><pub-id pub-id-type="pmid">16162884</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sankaran</surname> <given-names>VG</given-names></name><name><surname>Menne</surname> <given-names>TF</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Akie</surname> <given-names>TE</given-names></name><name><surname>Lettre</surname> <given-names>G</given-names></name><name><surname>Van Handel</surname> <given-names>B</given-names></name><name><surname>Mikkola</surname> <given-names>HK</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Cantor</surname> <given-names>AB</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A</article-title><source>Science</source><volume>322</volume><fpage>1839</fpage><lpage>1842</lpage><pub-id pub-id-type="doi">10.1126/science.1165409</pub-id><pub-id pub-id-type="pmid">19056937</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sankaran</surname> <given-names>VG</given-names></name><name><surname>Menne</surname> <given-names>TF</given-names></name><name><surname>Šćepanović</surname> <given-names>D</given-names></name><name><surname>Vergilio</surname> <given-names>JA</given-names></name><name><surname>Ji</surname> <given-names>P</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Thiru</surname> <given-names>P</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Lodish</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13</article-title><source>Proceedings of the National Academy of Sciences</source><volume>108</volume><fpage>1519</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1073/pnas.1018384108</pub-id><pub-id pub-id-type="pmid">21205891</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sankaran</surname> <given-names>VG</given-names></name><name><surname>Ludwig</surname> <given-names>LS</given-names></name><name><surname>Sicinska</surname> <given-names>E</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Bauer</surname> <given-names>DE</given-names></name><name><surname>Eng</surname> <given-names>JC</given-names></name><name><surname>Patterson</surname> <given-names>HC</given-names></name><name><surname>Metcalf</surname> <given-names>RA</given-names></name><name><surname>Natkunam</surname> <given-names>Y</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Sicinski</surname> <given-names>P</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Lodish</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number</article-title><source>Genes &amp; Development</source><volume>26</volume><fpage>2075</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1101/gad.197020.112</pub-id><pub-id pub-id-type="pmid">22929040</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sankaran</surname> <given-names>VG</given-names></name><name><surname>Joshi</surname> <given-names>M</given-names></name><name><surname>Agrawal</surname> <given-names>A</given-names></name><name><surname>Schmitz-Abe</surname> <given-names>K</given-names></name><name><surname>Towne</surname> <given-names>MC</given-names></name><name><surname>Marinakis</surname> <given-names>N</given-names></name><name><surname>Markianos</surname> <given-names>K</given-names></name><name><surname>Berry</surname> <given-names>GT</given-names></name><name><surname>Agrawal</surname> <given-names>PB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Rare complete loss of function provides insight into a pleiotropic genome-wide association study locus</article-title><source>Blood</source><volume>122</volume><fpage>3845</fpage><lpage>3847</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-09-528315</pub-id><pub-id pub-id-type="pmid">24288412</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeonov</surname> <given-names>DR</given-names></name><name><surname>Gowen</surname> <given-names>BG</given-names></name><name><surname>Boontanrart</surname> <given-names>M</given-names></name><name><surname>Roth</surname> <given-names>TL</given-names></name><name><surname>Gagnon</surname> <given-names>JD</given-names></name><name><surname>Mumbach</surname> <given-names>MR</given-names></name><name><surname>Satpathy</surname> <given-names>AT</given-names></name><name><surname>Lee</surname> <given-names>Y</given-names></name><name><surname>Bray</surname> <given-names>NL</given-names></name><name><surname>Chan</surname> <given-names>AY</given-names></name><name><surname>Lituiev</surname> <given-names>DS</given-names></name><name><surname>Nguyen</surname> <given-names>ML</given-names></name><name><surname>Gate</surname> <given-names>RE</given-names></name><name><surname>Subramaniam</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Woo</surname> <given-names>JM</given-names></name><name><surname>Mitros</surname> <given-names>T</given-names></name><name><surname>Ray</surname> <given-names>GJ</given-names></name><name><surname>Curie</surname> <given-names>GL</given-names></name><name><surname>Naddaf</surname> <given-names>N</given-names></name><name><surname>Chu</surname> <given-names>JS</given-names></name><name><surname>Ma</surname> <given-names>H</given-names></name><name><surname>Boyer</surname> <given-names>E</given-names></name><name><surname>Van Gool</surname> <given-names>F</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>R</given-names></name><name><surname>Tobin</surname> <given-names>VR</given-names></name><name><surname>Schumann</surname> <given-names>K</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Farh</surname> <given-names>KK</given-names></name><name><surname>Ansel</surname> <given-names>KM</given-names></name><name><surname>Ye</surname> <given-names>CJ</given-names></name><name><surname>Greenleaf</surname> <given-names>WJ</given-names></name><name><surname>Anderson</surname> <given-names>MS</given-names></name><name><surname>Bluestone</surname> <given-names>JA</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Corn</surname> <given-names>JE</given-names></name><name><surname>Marson</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Discovery of stimulation-responsive immune enhancers with CRISPR activation</article-title><source>Nature</source><volume>549</volume><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/nature23875</pub-id><pub-id pub-id-type="pmid">28854172</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smemo</surname> <given-names>S</given-names></name><name><surname>Tena</surname> <given-names>JJ</given-names></name><name><surname>Kim</surname> <given-names>KH</given-names></name><name><surname>Gamazon</surname> <given-names>ER</given-names></name><name><surname>Sakabe</surname> <given-names>NJ</given-names></name><name><surname>Gómez-Marín</surname> <given-names>C</given-names></name><name><surname>Aneas</surname> <given-names>I</given-names></name><name><surname>Credidio</surname> <given-names>FL</given-names></name><name><surname>Sobreira</surname> <given-names>DR</given-names></name><name><surname>Wasserman</surname> <given-names>NF</given-names></name><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Puviindran</surname> <given-names>V</given-names></name><name><surname>Tam</surname> <given-names>D</given-names></name><name><surname>Shen</surname> <given-names>M</given-names></name><name><surname>Son</surname> <given-names>JE</given-names></name><name><surname>Vakili</surname> <given-names>NA</given-names></name><name><surname>Sung</surname> <given-names>HK</given-names></name><name><surname>Naranjo</surname> <given-names>S</given-names></name><name><surname>Acemel</surname> <given-names>RD</given-names></name><name><surname>Manzanares</surname> <given-names>M</given-names></name><name><surname>Nagy</surname> <given-names>A</given-names></name><name><surname>Cox</surname> <given-names>NJ</given-names></name><name><surname>Hui</surname> <given-names>CC</given-names></name><name><surname>Gomez-Skarmeta</surname> <given-names>JL</given-names></name><name><surname>Nóbrega</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Obesity-associated variants within FTO form long-range functional connections with IRX3</article-title><source>Nature</source><volume>507</volume><fpage>371</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature13138</pub-id><pub-id pub-id-type="pmid">24646999</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname> <given-names>D</given-names></name><name><surname>Morris</surname> <given-names>JH</given-names></name><name><surname>Cook</surname> <given-names>H</given-names></name><name><surname>Kuhn</surname> <given-names>M</given-names></name><name><surname>Wyder</surname> <given-names>S</given-names></name><name><surname>Simonovic</surname> <given-names>M</given-names></name><name><surname>Santos</surname> <given-names>A</given-names></name><name><surname>Doncheva</surname> <given-names>NT</given-names></name><name><surname>Roth</surname> <given-names>A</given-names></name><name><surname>Bork</surname> <given-names>P</given-names></name><name><surname>Jensen</surname> <given-names>LJ</given-names></name><name><surname>von Mering</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>D362</fpage><lpage>D368</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw937</pub-id><pub-id pub-id-type="pmid">27924014</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tewhey</surname> <given-names>R</given-names></name><name><surname>Kotliar</surname> <given-names>D</given-names></name><name><surname>Park</surname> <given-names>DS</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Winnicki</surname> <given-names>S</given-names></name><name><surname>Reilly</surname> <given-names>SK</given-names></name><name><surname>Andersen</surname> <given-names>KG</given-names></name><name><surname>Mikkelsen</surname> <given-names>TS</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Schaffner</surname> <given-names>SF</given-names></name><name><surname>Sabeti</surname> <given-names>PC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Direct identification of hundreds of Expression-Modulating variants using a multiplexed reporter assay</article-title><source>Cell</source><volume>165</volume><fpage>1519</fpage><lpage>1529</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.04.027</pub-id><pub-id pub-id-type="pmid">27259153</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname> <given-names>SK</given-names></name><name><surname>Ceroni</surname> <given-names>A</given-names></name><name><surname>van de Bunt</surname> <given-names>M</given-names></name><name><surname>Burrows</surname> <given-names>C</given-names></name><name><surname>Barrett</surname> <given-names>A</given-names></name><name><surname>Scharfmann</surname> <given-names>R</given-names></name><name><surname>Ebner</surname> <given-names>D</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Systematic functional characterization of candidate causal genes for type 2 diabetes risk variants</article-title><source>Diabetes</source><volume>65</volume><fpage>3805</fpage><lpage>3811</lpage><pub-id pub-id-type="doi">10.2337/db16-0361</pub-id><pub-id pub-id-type="pmid">27554474</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname> <given-names>PY</given-names></name><name><surname>Parker</surname> <given-names>AE</given-names></name><name><surname>Lee</surname> <given-names>JS</given-names></name><name><surname>Trussell</surname> <given-names>C</given-names></name><name><surname>Sharif</surname> <given-names>O</given-names></name><name><surname>Luna</surname> <given-names>F</given-names></name><name><surname>Federe</surname> <given-names>G</given-names></name><name><surname>Barnes</surname> <given-names>SW</given-names></name><name><surname>Walker</surname> <given-names>JR</given-names></name><name><surname>Vance</surname> <given-names>J</given-names></name><name><surname>Gao</surname> <given-names>MY</given-names></name><name><surname>Klock</surname> <given-names>HE</given-names></name><name><surname>Clarkson</surname> <given-names>S</given-names></name><name><surname>Russ</surname> <given-names>C</given-names></name><name><surname>Miraglia</surname> <given-names>LJ</given-names></name><name><surname>Cooke</surname> <given-names>MP</given-names></name><name><surname>Boitano</surname> <given-names>AE</given-names></name><name><surname>McNamara</surname> <given-names>P</given-names></name><name><surname>Lamb</surname> <given-names>J</given-names></name><name><surname>Schmedt</surname> <given-names>C</given-names></name><name><surname>Snead</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Guide swap enables genome-scale pooled CRISPR-Cas9 screening in human primary cells</article-title><source>Nature Methods</source><volume>15</volume><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/s41592-018-0149-1</pub-id><pub-id pub-id-type="pmid">30297964</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsherniak</surname> <given-names>A</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Montgomery</surname> <given-names>PG</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Kryukov</surname> <given-names>G</given-names></name><name><surname>Cowley</surname> <given-names>GS</given-names></name><name><surname>Gill</surname> <given-names>S</given-names></name><name><surname>Harrington</surname> <given-names>WF</given-names></name><name><surname>Pantel</surname> <given-names>S</given-names></name><name><surname>Krill-Burger</surname> <given-names>JM</given-names></name><name><surname>Meyers</surname> <given-names>RM</given-names></name><name><surname>Ali</surname> <given-names>L</given-names></name><name><surname>Goodale</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Hsiao</surname> <given-names>J</given-names></name><name><surname>Gerath</surname> <given-names>WFJ</given-names></name><name><surname>Howell</surname> <given-names>S</given-names></name><name><surname>Merkel</surname> <given-names>E</given-names></name><name><surname>Ghandi</surname> <given-names>M</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defining a cancer dependency map</article-title><source>Cell</source><volume>170</volume><fpage>564</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id><pub-id pub-id-type="pmid">28753430</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Nandakumar</surname> <given-names>SK</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Giani</surname> <given-names>FC</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Rogov</surname> <given-names>P</given-names></name><name><surname>Melnikov</surname> <given-names>A</given-names></name><name><surname>McDonel</surname> <given-names>P</given-names></name><name><surname>Do</surname> <given-names>R</given-names></name><name><surname>Mikkelsen</surname> <given-names>TS</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Systematic functional dissection of common genetic variation affecting red blood cell traits</article-title><source>Cell</source><volume>165</volume><fpage>1530</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.04.048</pub-id><pub-id pub-id-type="pmid">27259154</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Verboon</surname> <given-names>JM</given-names></name><name><surname>Kazerounian</surname> <given-names>S</given-names></name><name><surname>Guo</surname> <given-names>MH</given-names></name><name><surname>Yuan</surname> <given-names>D</given-names></name><name><surname>Ludwig</surname> <given-names>LS</given-names></name><name><surname>Handsaker</surname> <given-names>RE</given-names></name><name><surname>Abdulhay</surname> <given-names>NJ</given-names></name><name><surname>Fiorini</surname> <given-names>C</given-names></name><name><surname>Genovese</surname> <given-names>G</given-names></name><name><surname>Lim</surname> <given-names>ET</given-names></name><name><surname>Cheng</surname> <given-names>A</given-names></name><name><surname>Cummings</surname> <given-names>BB</given-names></name><name><surname>Chao</surname> <given-names>KR</given-names></name><name><surname>Beggs</surname> <given-names>AH</given-names></name><name><surname>Genetti</surname> <given-names>CA</given-names></name><name><surname>Sieff</surname> <given-names>CA</given-names></name><name><surname>Newburger</surname> <given-names>PE</given-names></name><name><surname>Niewiadomska</surname> <given-names>E</given-names></name><name><surname>Matysiak</surname> <given-names>M</given-names></name><name><surname>Vlachos</surname> <given-names>A</given-names></name><name><surname>Lipton</surname> <given-names>JM</given-names></name><name><surname>Atsidaftos</surname> <given-names>E</given-names></name><name><surname>Glader</surname> <given-names>B</given-names></name><name><surname>Narla</surname> <given-names>A</given-names></name><name><surname>Gleizes</surname> <given-names>PE</given-names></name><name><surname>O'Donohue</surname> <given-names>MF</given-names></name><name><surname>Montel-Lehry</surname> <given-names>N</given-names></name><name><surname>Amor</surname> <given-names>DJ</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name><name><surname>O'Donnell-Luria</surname> <given-names>AH</given-names></name><name><surname>Gupta</surname> <given-names>N</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>MacArthur</surname> <given-names>DG</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Lek</surname> <given-names>M</given-names></name><name><surname>Da Costa</surname> <given-names>L</given-names></name><name><surname>Nathan</surname> <given-names>DG</given-names></name><name><surname>Korostelev</surname> <given-names>AA</given-names></name><name><surname>Do</surname> <given-names>R</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name><name><surname>Gazda</surname> <given-names>HT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The genetic landscape of Diamond-Blackfan anemia</article-title><source>The American Journal of Human Genetics</source><volume>103</volume><fpage>930</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2018.10.027</pub-id><pub-id pub-id-type="pmid">30503522</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Lareau</surname> <given-names>CA</given-names></name><name><surname>Bao</surname> <given-names>EL</given-names></name><name><surname>Ludwig</surname> <given-names>LS</given-names></name><name><surname>Guo</surname> <given-names>MH</given-names></name><name><surname>Benner</surname> <given-names>C</given-names></name><name><surname>Satpathy</surname> <given-names>AT</given-names></name><name><surname>Kartha</surname> <given-names>VK</given-names></name><name><surname>Salem</surname> <given-names>RM</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Finucane</surname> <given-names>HK</given-names></name><name><surname>Aryee</surname> <given-names>MJ</given-names></name><name><surname>Buenrostro</surname> <given-names>JD</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interrogation of human hematopoiesis at single-cell and single-variant resolution</article-title><source>Nature Genetics</source><volume>51</volume><fpage>683</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0362-6</pub-id><pub-id pub-id-type="pmid">30858613</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Harst</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Mateo Leach</surname> <given-names>I</given-names></name><name><surname>Rendon</surname> <given-names>A</given-names></name><name><surname>Verweij</surname> <given-names>N</given-names></name><name><surname>Sehmi</surname> <given-names>J</given-names></name><name><surname>Paul</surname> <given-names>DS</given-names></name><name><surname>Elling</surname> <given-names>U</given-names></name><name><surname>Allayee</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Radhakrishnan</surname> <given-names>A</given-names></name><name><surname>Tan</surname> <given-names>ST</given-names></name><name><surname>Voss</surname> <given-names>K</given-names></name><name><surname>Weichenberger</surname> <given-names>CX</given-names></name><name><surname>Albers</surname> <given-names>CA</given-names></name><name><surname>Al-Hussani</surname> <given-names>A</given-names></name><name><surname>Asselbergs</surname> <given-names>FW</given-names></name><name><surname>Ciullo</surname> <given-names>M</given-names></name><name><surname>Danjou</surname> <given-names>F</given-names></name><name><surname>Dina</surname> <given-names>C</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Evans</surname> <given-names>DM</given-names></name><name><surname>Franke</surname> <given-names>L</given-names></name><name><surname>Gögele</surname> <given-names>M</given-names></name><name><surname>Hartiala</surname> <given-names>J</given-names></name><name><surname>Hersch</surname> <given-names>M</given-names></name><name><surname>Holm</surname> <given-names>H</given-names></name><name><surname>Hottenga</surname> <given-names>JJ</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Kleber</surname> <given-names>ME</given-names></name><name><surname>Lagou</surname> <given-names>V</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Lopez</surname> <given-names>LM</given-names></name><name><surname>Lyytikäinen</surname> <given-names>LP</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Murgia</surname> <given-names>F</given-names></name><name><surname>Nolte</surname> <given-names>IM</given-names></name><name><surname>O'Reilly</surname> <given-names>PF</given-names></name><name><surname>Padmanabhan</surname> <given-names>S</given-names></name><name><surname>Parsa</surname> <given-names>A</given-names></name><name><surname>Pirastu</surname> <given-names>N</given-names></name><name><surname>Porcu</surname> <given-names>E</given-names></name><name><surname>Portas</surname> <given-names>L</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Ried</surname> <given-names>JS</given-names></name><name><surname>Shin</surname> <given-names>SY</given-names></name><name><surname>Tang</surname> <given-names>CS</given-names></name><name><surname>Teumer</surname> <given-names>A</given-names></name><name><surname>Traglia</surname> <given-names>M</given-names></name><name><surname>Ulivi</surname> <given-names>S</given-names></name><name><surname>Westra</surname> <given-names>HJ</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>JH</given-names></name><name><surname>Anni</surname> <given-names>F</given-names></name><name><surname>Abdellaoui</surname> <given-names>A</given-names></name><name><surname>Attwood</surname> <given-names>A</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Bandinelli</surname> <given-names>S</given-names></name><name><surname>Bastardot</surname> <given-names>F</given-names></name><name><surname>Benyamin</surname> <given-names>B</given-names></name><name><surname>Boehm</surname> <given-names>BO</given-names></name><name><surname>Cookson</surname> <given-names>WO</given-names></name><name><surname>Das</surname> <given-names>D</given-names></name><name><surname>de Bakker</surname> <given-names>PI</given-names></name><name><surname>de Boer</surname> <given-names>RA</given-names></name><name><surname>de Geus</surname> <given-names>EJ</given-names></name><name><surname>de Moor</surname> <given-names>MH</given-names></name><name><surname>Dimitriou</surname> <given-names>M</given-names></name><name><surname>Domingues</surname> <given-names>FS</given-names></name><name><surname>Döring</surname> <given-names>A</given-names></name><name><surname>Engström</surname> <given-names>G</given-names></name><name><surname>Eyjolfsson</surname> <given-names>GI</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Fischer</surname> <given-names>K</given-names></name><name><surname>Galanello</surname> <given-names>R</given-names></name><name><surname>Garner</surname> <given-names>SF</given-names></name><name><surname>Genser</surname> <given-names>B</given-names></name><name><surname>Gibson</surname> <given-names>QD</given-names></name><name><surname>Girotto</surname> <given-names>G</given-names></name><name><surname>Gudbjartsson</surname> <given-names>DF</given-names></name><name><surname>Harris</surname> <given-names>SE</given-names></name><name><surname>Hartikainen</surname> <given-names>AL</given-names></name><name><surname>Hastie</surname> <given-names>CE</given-names></name><name><surname>Hedblad</surname> <given-names>B</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Jolley</surname> <given-names>J</given-names></name><name><surname>Kähönen</surname> <given-names>M</given-names></name><name><surname>Kema</surname> <given-names>IP</given-names></name><name><surname>Kemp</surname> <given-names>JP</given-names></name><name><surname>Liang</surname> <given-names>L</given-names></name><name><surname>Lloyd-Jones</surname> <given-names>H</given-names></name><name><surname>Loos</surname> <given-names>RJ</given-names></name><name><surname>Meacham</surname> <given-names>S</given-names></name><name><surname>Medland</surname> <given-names>SE</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Memari</surname> <given-names>Y</given-names></name><name><surname>Mihailov</surname> <given-names>E</given-names></name><name><surname>Miller</surname> <given-names>K</given-names></name><name><surname>Moffatt</surname> <given-names>MF</given-names></name><name><surname>Nauck</surname> <given-names>M</given-names></name><name><surname>Novatchkova</surname> <given-names>M</given-names></name><name><surname>Nutile</surname> <given-names>T</given-names></name><name><surname>Olafsson</surname> <given-names>I</given-names></name><name><surname>Onundarson</surname> <given-names>PT</given-names></name><name><surname>Parracciani</surname> <given-names>D</given-names></name><name><surname>Penninx</surname> <given-names>BW</given-names></name><name><surname>Perseu</surname> <given-names>L</given-names></name><name><surname>Piga</surname> <given-names>A</given-names></name><name><surname>Pistis</surname> <given-names>G</given-names></name><name><surname>Pouta</surname> <given-names>A</given-names></name><name><surname>Puc</surname> <given-names>U</given-names></name><name><surname>Raitakari</surname> <given-names>O</given-names></name><name><surname>Ring</surname> <given-names>SM</given-names></name><name><surname>Robino</surname> <given-names>A</given-names></name><name><surname>Ruggiero</surname> <given-names>D</given-names></name><name><surname>Ruokonen</surname> <given-names>A</given-names></name><name><surname>Saint-Pierre</surname> <given-names>A</given-names></name><name><surname>Sala</surname> <given-names>C</given-names></name><name><surname>Salumets</surname> <given-names>A</given-names></name><name><surname>Sambrook</surname> <given-names>J</given-names></name><name><surname>Schepers</surname> <given-names>H</given-names></name><name><surname>Schmidt</surname> <given-names>CO</given-names></name><name><surname>Silljé</surname> <given-names>HH</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Smit</surname> <given-names>JH</given-names></name><name><surname>Starr</surname> <given-names>JM</given-names></name><name><surname>Stephens</surname> <given-names>J</given-names></name><name><surname>Sulem</surname> <given-names>P</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Tragante</surname> <given-names>V</given-names></name><name><surname>van Gilst</surname> <given-names>WH</given-names></name><name><surname>van Pelt</surname> <given-names>LJ</given-names></name><name><surname>van Veldhuisen</surname> <given-names>DJ</given-names></name><name><surname>Völker</surname> <given-names>U</given-names></name><name><surname>Whitfield</surname> <given-names>JB</given-names></name><name><surname>Willemsen</surname> <given-names>G</given-names></name><name><surname>Winkelmann</surname> <given-names>BR</given-names></name><name><surname>Wirnsberger</surname> <given-names>G</given-names></name><name><surname>Algra</surname> <given-names>A</given-names></name><name><surname>Cucca</surname> <given-names>F</given-names></name><name><surname>d'Adamo</surname> <given-names>AP</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Deary</surname> <given-names>IJ</given-names></name><name><surname>Dominiczak</surname> <given-names>AF</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Fortina</surname> <given-names>P</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Gasparini</surname> <given-names>P</given-names></name><name><surname>Greinacher</surname> <given-names>A</given-names></name><name><surname>Hazen</surname> <given-names>SL</given-names></name><name><surname>Jarvelin</surname> <given-names>MR</given-names></name><name><surname>Khaw</surname> <given-names>KT</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Maerz</surname> <given-names>W</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Mitchell</surname> <given-names>BD</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>Moore</surname> <given-names>C</given-names></name><name><surname>Navis</surname> <given-names>G</given-names></name><name><surname>Pirastu</surname> <given-names>M</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Ramirez-Solis</surname> <given-names>R</given-names></name><name><surname>Schadt</surname> <given-names>E</given-names></name><name><surname>Scott</surname> <given-names>J</given-names></name><name><surname>Shuldiner</surname> <given-names>AR</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Smith</surname> <given-names>JG</given-names></name><name><surname>Snieder</surname> <given-names>H</given-names></name><name><surname>Sorice</surname> <given-names>R</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Stumvoll</surname> <given-names>M</given-names></name><name><surname>Tang</surname> <given-names>WH</given-names></name><name><surname>Toniolo</surname> <given-names>D</given-names></name><name><surname>Tönjes</surname> <given-names>A</given-names></name><name><surname>Visscher</surname> <given-names>PM</given-names></name><name><surname>Vollenweider</surname> <given-names>P</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Wolffenbuttel</surname> <given-names>BH</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Beckmann</surname> <given-names>JS</given-names></name><name><surname>Dedoussis</surname> <given-names>GV</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Ferreira</surname> <given-names>MA</given-names></name><name><surname>Sanna</surname> <given-names>S</given-names></name><name><surname>Uda</surname> <given-names>M</given-names></name><name><surname>Hicks</surname> <given-names>AA</given-names></name><name><surname>Penninger</surname> <given-names>JM</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Kooner</surname> <given-names>JS</given-names></name><name><surname>Ouwehand</surname> <given-names>WH</given-names></name><name><surname>Soranzo</surname> <given-names>N</given-names></name><name><surname>Chambers</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Seventy-five genetic loci influencing the human red blood cell</article-title><source>Nature</source><volume>492</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature11677</pub-id><pub-id pub-id-type="pmid">23222517</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veyrieras</surname> <given-names>JB</given-names></name><name><surname>Kudaravalli</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>SY</given-names></name><name><surname>Dermitzakis</surname> <given-names>ET</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name><name><surname>Stephens</surname> <given-names>M</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>High-resolution mapping of expression-QTLs yields insight into human gene regulation</article-title><source>PLOS Genetics</source><volume>4</volume><elocation-id>e1000214</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000214</pub-id><pub-id pub-id-type="pmid">18846210</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vockley</surname> <given-names>CM</given-names></name><name><surname>Guo</surname> <given-names>C</given-names></name><name><surname>Majoros</surname> <given-names>WH</given-names></name><name><surname>Nodzenski</surname> <given-names>M</given-names></name><name><surname>Scholtens</surname> <given-names>DM</given-names></name><name><surname>Hayes</surname> <given-names>MG</given-names></name><name><surname>Lowe</surname> <given-names>WL</given-names></name><name><surname>Reddy</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Massively parallel quantification of the regulatory effects of noncoding genetic variation in a human cohort</article-title><source>Genome Research</source><volume>25</volume><fpage>1206</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1101/gr.190090.115</pub-id><pub-id pub-id-type="pmid">26084464</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Birsoy</surname> <given-names>K</given-names></name><name><surname>Hughes</surname> <given-names>NW</given-names></name><name><surname>Krupczak</surname> <given-names>KM</given-names></name><name><surname>Post</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>JJ</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification and characterization of essential genes in the human genome</article-title><source>Science</source><volume>350</volume><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1126/science.aac7041</pub-id><pub-id pub-id-type="pmid">26472758</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Angelis</surname> <given-names>N</given-names></name><name><surname>Thein</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MYB - A regulatory factor in hematopoiesis</article-title><source>Gene</source><volume>665</volume><fpage>6</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2018.04.065</pub-id><pub-id pub-id-type="pmid">29704633</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whalen</surname> <given-names>S</given-names></name><name><surname>Pollard</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Most chromatin interactions are not in linkage disequilibrium</article-title><source>Genome Research</source><volume>29</volume><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1101/gr.238022.118</pub-id><pub-id pub-id-type="pmid">30617125</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>H</given-names></name><name><surname>Hale</surname> <given-names>J</given-names></name><name><surname>Jaffray</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>An</surname> <given-names>X</given-names></name><name><surname>Hillyer</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>N</given-names></name><name><surname>Kinet</surname> <given-names>S</given-names></name><name><surname>Taylor</surname> <given-names>N</given-names></name><name><surname>Mohandas</surname> <given-names>N</given-names></name><name><surname>Narla</surname> <given-names>A</given-names></name><name><surname>Blanc</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Developmental differences between neonatal and adult human erythropoiesis</article-title><source>American Journal of Hematology</source><volume>93</volume><fpage>494</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1002/ajh.25015</pub-id><pub-id pub-id-type="pmid">29274096</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.44080.040</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Parker</surname><given-names>Stephen</given-names></name><role>Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Stephen Parker as the Reviewing Editor, and the evaluation has been overseen by Mark McCarthy as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>Nandakumar et al. set out to study RBC GWAS signals in a model system of HSPCs differentiated to the erythroid lineage. They select ~400 genes across 75 loci and perform a shRNA screen quantifying shRNA abundance across differentiation time points. Their screen identifies 77 gene hits at 38 loci and they follow-up with some biological insight into two of these genes (TFR2 and SF3A2). Overall, this innovative approach provides a nice model for the field but we are unsure about a few important items that we elaborate on below.</p><p>Essential revisions:</p><p>1) The idea used to set up the screen and motivate gene selection by looking in the LD/recombination block needs to be further justified. Given most GWAS hits are non-coding, what is the any strong reason to assume the block must extend to the target gene, and how do we know most GWAS are not like the FTO locus that interacts with far-away genes? This is something that should be justified early on. As-is, this idea is only mentioned briefly in the Discussion.</p><p>2) As a corollary to point 1, a more conventional approach to connect GWAS to target genes is through eQTL analyses. Did the authors look at eQTL in whole blood (for which there are large data sets available) or other relevant cell types? How concordant are eQTL nominated genes with the genes revealed in the shRNA screen? The status of overlap and missingness would both be interesting to comment on here. Further, where eQTL data can nominate a target gene and the gene emerges from the shRNA screen, does the eQTL allelic direction of the RBC trait lead to reduced target gene expression (which would be consistent with the knock-down effects of shRNA treatment)? If the allelic direction of effect is different, how does one interpret this?</p><p>3) The screen quantified shRNA abundance as a function of erythroid differentiation and they identified targets that were either enriched or depleted late in the differentiation process. It is unclear what the significance of being enriched or depleted in the library means in terms of erythroid differentiation. Are there known genes that have biological functions which are expected to be enriched and depleted if they are depleted by shRNA?</p><p>4) Why do the authors use shRNA instead of CRISPR knockout or knockdown? There are numerous references (going back to early 2000s) documenting off-target effects of shRNA, so it is puzzling why this choice was made. For example, this recent preprint from George Daley's lab: &quot;Short hairpin RNAs artifactually impair cell growth and suppress clustered microRNA expression.&quot; https://www.biorxiv.org/content/early/2018/12/11/372920 Given the &quot;artifactual impair[ment] of cell growth&quot; with shRNA, do the authors feel that their primary readout (growth) can be trusted given the shRNA perturbation?</p><p>5) Related to the concern mentioned in point 5, the authors should consider using CRISPRi (or CRISPR) to validate a subset of loci. Perhaps the two genes they've already focused on at the end. If such data are already (nearly) available (maybe in anticipation of such a reviewer comment), we encourage the authors to include it in this work. Although we list this in the essential revisions section and feel strongly about it, we realize this work may not be feasible within two months. If that's the case, we expect strong justification and text that directly addresses the point of shRNA vs CRISPR(i) screening approaches.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.44080.041</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The idea used to set up the screen and motivate gene selection by looking in the LD/recombination block needs to be further justified. Given most GWAS hits are non-coding, what is the any strong reason to assume the block must extend to the target gene, and how do we know most GWAS are not like the FTO locus that interacts with far-away genes? This is something that should be justified early on. As-is, this idea is only mentioned briefly in the Discussion.</p></disp-quote><p>Thank you for identifying this as an area for further clarification. While the method we use to nominate genes included in the shRNA screen may miss longer range interactions, when the screen was designed it seemed to represent a reasonable approach to capture a portion of the genetic targets for non-coding genetic variants and was similar to other approaches used to nominate genes that had been described in the literature. Since the screen was designed and executed, studies like Whalen and Pollard, 2019 have emerged which provide an enhanced sense of which topological tools at our disposal can offer the most comprehensive approach to target selection. While the use of strong LD partners by itself may not capture a majority of gene targets, by supplementing it with extension to the nearest recombination junctions and by adding wingspans on to the 5’ and 3’ end of candidate genes, we do actually enter into a regime where we would estimate we could resolve over half of likely targets. In Whalen and Pollard, 2019, the median eQTL distance is noted to be 49 kb, which falls well within the bulk of our probability density for the size of the SNP windows we are generating. Regardless, we agree that this issue could have been explored more deeply in the text, so we have made amendments to reflect that discussion.</p><p>Results:</p><p>“We endeavored to select candidate genes that could potentially underlie these 75 GWAS signals. […] However there still exists a nontrivial amount of valid targets within reach of proximity LD approaches, especially when the calculation of such windows are extended to reach the nearest recombination hotspot, suggesting that our approach would capture many candidate target genes.”</p><disp-quote content-type="editor-comment"><p>2) As a corollary to point 1, a more conventional approach to connect GWAS to target genes is through eQTL analyses. Did the authors look at eQTL in whole blood (for which there are large data sets available) or other relevant cell types? How concordant are eQTL nominated genes with the genes revealed in the shRNA screen? The status of overlap and missingness would both be interesting to comment on here. Further, where eQTL data can nominate a target gene and the gene emerges from the shRNA screen, does the eQTL allelic direction of the RBC trait lead to reduced target gene expression (which would be consistent with the knock-down effects of shRNA treatment)? If the allelic direction of effect is different, how does one interpret this?</p></disp-quote><p>To examine the eQTL-based approach and how it might relate to our results, we took the whole blood gene expression summary statistics from GTEx and intersected them with genomic regions in linkage disequilibrium r<sup>2</sup> &gt; 0.8 with the 75 sentinel SNPs from van der Harst et al. study used to identify the library of genes targeted in the screen (see Figure 1A). These regions were padded to a fixed 100 kb, as many of the regions are fairly small. This yielded 139 genes that one could argue would be nominated on an eQTL-basis from the total pool of 8661 examined. We performed a Fisher’s exact test on the contingency table comparing hits from our method of nomination with the set of eQTLs and eQTL-nominated genes. There were 35 hits (of the 77 total in our screen) present among the whole eQTL set, but 0 hits found among the 139 genes nominated by using eQTLs from whole blood. Thus, there was no appreciable connection between the eQTL-based method and our nomination method. We suggest that this observation also emphasizes how studies of variation in developing hematopoietic cells may not be accurately reflected by studies of circulating blood cells. We are looking at erythroblasts which are essentially not present in whole blood, so one would expect to miss cell type specific effects or eQTLs that act in early progenitor populations. Substantial additional work would be required to disentangle this further, but this is in keeping with our position that our nomination approach offers valuable information that is complementary to other typical means of nomination.</p><disp-quote content-type="editor-comment"><p>3) The screen quantified shRNA abundance as a function of erythroid differentiation and they identified targets that were either enriched or depleted late in the differentiation process. It is unclear what the significance of being enriched or depleted in the library means in terms of erythroid differentiation. Are there known genes that have biological functions which are expected to be enriched and depleted if they are depleted by shRNA?</p></disp-quote><p>We apologize if we did not do an adequate job elaborating on this in the text and connecting to the relevant panels (especially Figure 2C-E). We have made a number of changes which we hope address this point by more explicitly highlighting the outcomes of the included controls.</p><p>Results:</p><p>“Mobilized peripheral blood-derived primary human CD34<sup>+</sup> HSPCs from 3 independent healthy donors were infected with a lentiviral-based pooled shRNA library consisting of 2803 hairpins targeting the 389 GWAS-nominated genes, along with 30 control genes (Moffat et al., 2006). […] The set of control shRNAs encompassed essential housekeeping genes as positive controls, negative controls in the form of luciferase and other genes not expressed in humans, and a well-established set of genes known to be important for erythropoiesis (erythroid controls) (Figure 1B).”</p><p>“The infected HSPCs were cultured using a three-phase semi-synchronous erythroid differentiation method where differentiation blockade reduces cell numbers either through cell death or through a failure of proliferation (Giani et al., 2016; Hu et al., 2013). We hypothesized that hairpins targeting potential regulators of erythropoiesis would be depleted or enriched during the three-phase erythroid culture, similar to our prior experience in analyzing specific GWAS-nominated genes (Giani et al., 2016; Sankaran et al., 2012; Ulirsch et al., 2016).”</p><p>“The tested set of hairpins targeting genes nominated by the 75 loci showed a variety of activities, forming a broad distribution spanning both decreases and increases in abundance at different time points (Figure 2B). […] Hairpins targeting genes with known biological roles in erythropoiesis, such as GATA1 and RPS19 (Khajuria et al., 2018; Ludwig et al., 2014), showed markedly decreased abundance across the time course.”</p><disp-quote content-type="editor-comment"><p>4) Why do the authors use shRNA instead of CRISPR knockout or knockdown? There are numerous references (going back to early 2000s) documenting off-target effects of shRNA, so it is puzzling why this choice was made. For example, this recent preprint from George Daley's lab: &quot;Short hairpin RNAs artifactually impair cell growth and suppress clustered microRNA expression.&quot; https://www.biorxiv.org/content/early/2018/12/11/372920 Given the &quot;artifactual impair[ment] of cell growth&quot; with shRNA, do the authors feel that their primary readout (growth) can be trusted given the shRNA perturbation?</p></disp-quote><p>We understand the reviewers’ concern that shRNAs can have off-target effects and can impair cell growth. CRISPR based screening approaches can potentially overcome these issues. We chose to perform our screen in primary human CD34<sup>+</sup> hematopoietic stem and progenitor cells (HSPCs), instead of using cell lines, to identify the bonafide regulators of erythropoiesis that could underlie common genetic variation. We have tested both CRISPR and shRNA-based approaches in primary HSPCs and our data, which we now added to Figure 1—figure supplement 2, suggest that CRISPR based pooled screens are not feasible to perform in primary HSPCs, given low levels of infection that are achieved. On the other hand, in our experience, results from shRNA experiments can be independently validated using CRISPR based approaches (Gianni et al., 2016). These results have motivated us to perform an shRNA screen in primary HSPCs and we can increase our confidence in the growth readout by employing 5-7 shRNAs per gene and compared them against a pool of negative control shRNAs.</p><p>We observe that all in one CRISPR/ CRISPRi lentiviral constructs are produced at lower viral titer (~5e5 infectious units /ml unconcentrated) compared to shRNA constructs (~ 9e6 infectious units /ml unconcentrated). This is likely due, at least in part, to reduced packaging ability, owing to the large size of the Cas9 cDNA (~4.2kb) compared to shRNAs (21bp) (Figure 1—figure supplement 2A). This low viral titer becomes a bottleneck when performing CRISPR screens in primary CD34<sup>+</sup> HSPCs that require high multiplicities of infection (MOI) for successful gene transfer compared to rapidly dividing cell lines that require a low MOI.</p><p>In our initial studies, we observed that shRNA constructs were able to achieve good infectivity in CD34<sup>+</sup> HSPCs at low MOI (40-60% infectivity at MOI ~20) (Figure 1—figure supplement 2B). On the other hand, CRISPR/CRISPRi constructs require very high MOI (20- 30% infectivity at MOI 150) to achieve reasonable infectivity. We also observe that CRISPRi based approaches gave uniform knockdown compared to cutting with CRIPSR/Cas9 when we targeted a surface antigen, Duffy/DARC (Figure 1—figure supplement 2C). Based on our calculations we would require 3000 ml of virus to perform just one replicate (10 e6 CD34<sup>+</sup> cells) of a CRISPR/CRISPRi based screen with sufficient library representation, which would certainly stretch and likely exceed what we are capable of achieving reasonably for such a functional screen.</p><p>A recent study published a few months ago has overcome this bottleneck by electroporation of Cas9 as a protein followed by infection with a pooled sgRNA lentiviral library, which can be produced at higher viral titers (Ting et al., 2019). This could be a promising means to use CRISPR in future screening approaches, although this approach is not available in the CRISPRi format.</p><p>Results:</p><p>“Since the majority of common genetic variation underlying RBC traits appears to act in a cell-intrinsic manner within the erythroid lineage, we decided to perturb the candidate genes during the process of human erythropoiesis (Giani et al., 2016, Sankaran et al., 2012, Sankaran et al., 2008, Ulirsch et al., 2016). […] Furthermore, shRNAs can act rapidly to achieve gene knockdown and thereby avoid compensatory effects that can occur when complete CRISPR knockout is achieved (Rossi et al., 2015), better recapitulating the subtle changes in gene expression that are characteristic of common genetic variation.”</p><p><italic>5) Related to the concern mentioned in point 5, the authors should consider using CRISPRi (or CRISPR) to validate a subset of loci. Perhaps the two genes they've already focused on at the end. If such data are already (nearly) available (maybe in anticipation of such a reviewer comment), we encourage the authors to include it in this work. Although we list this in the essential revisions section and feel strongly about it, we realize this work may not be feasible within two months. If that's the case, we expect strong justification and text that directly addresses the point of shRNA vs CRISPR(i) screening approaches.</italic> </p><p>We appreciate this question to validate the shRNA screen results using orthogonal approaches such as CRISPR or CRISPRi. To this end, we have attempted to knockout one of the hits from the screen (TFR2) in HSPCs using Cas9 ribonucleoprotein (RNP) nucleofection. We selected 3 guides targeting TFR2 with high on-target scores based on the metrics reported by Doench et al., Nature Biotechnology, 2016. While we did observe reasonable editing rates, these were not stable over the time course of the experiment for currently unclear reasons. Since the edits are not stable, the outcomes of these experiments are hard to decipher without extensive additional characterization.</p></body></sub-article></article>